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Limin Zhu, B.A. 
Supervisory Professor: Dennis P. M. Hughes, M.D. Ph.D. 
 
Osteosarcoma is a highly invasive bone malignancy in which metastasis accounts for 
the vast majority of death and morbidity in patients. Understanding the mechanisms 
controlling metastasis is essential for improving patient survival in this disease. In order to 
improve the clinical outcomes for patients with poor prognosis, it is urgent to find new 
therapeutic targets to block metastasis in this disease. Recent studies have shown that 
Metadherin (MTDH) plays an essential role in mediating tumorigenesis and metastasis in a 
variety of human cancers. Our study assessed the role of MTDH in osteosarcoma metastasis 
and elucidated the mechanisms underlying its metastasis-promoting activity. 
To evaluate the expression of MTDH in primary and metastatic lesions of 
osteosarcoma, two tissue microarrays containing patient-derived primary and metastatic 
tumor specimens were examined by immunohistochemical staining with anti-MTDH 
antibody. We also examined MTDH in a cDNA array expression database made from 
pretreatment diagnostic biopsies of high-grade osteosarcoma patients to further assess the 
correlation between MTDH expression and clinical outcome. We used western blot, qPCR, 
and flow cytometry to measure the expression of MTDH in a panel of osteosarcoma cell 
lines. In parallel experiments we used MTDH-specific shRNA to reduce endogenous MTDH 
expression, and blocked cell surface MTDH by anti-MTDH antibodies. The impact of 
MTDH inhibition was assessed in vitro using transwell migration assays and matrigel 
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invasion assays. In addition, we developed an orthotopic xenograft mouse model to study the 
relationship between MTDH expression and osteosarcoma pulmonary metastasis. To 
investigate the role of MTDH in cell-extracellular matrix (ECM) interaction and to identify 
the extracellular binding partner for cell surface MTDH, a series of adhesion assays were 
performed, followed by bidirectional co-immunoprecipitation. 
We have demonstrated that MTDH is up-regulated in human osteosarcoma cell lines 
and patient-derived specimens compared with normal human osteoblasts. Overexpression of 
MTDH is more profound in metastatic lesions compared to primary tumors and is correlated 
with poor clinical outcomes in osteosarcoma patients. MTDH knockdown and blockade of 
cell surface MTDH significantly reduced migration and invasion in osteosarcoma cells. In 
the in vivo experiments, down-regulation of MTDH in osteosarcoma cells delayed primary 
tumor growth and prohibited pulmonary metastasis. Both in vitro and in vivo studies 
confirmed the critical role of MTDH in the invasive and metastatic capacity of osteosarcoma 
cells. More importantly, we have identified the significance of cell surface localization of 
MTDH in mediating osteosarcoma motility and invasiveness. We showed that MTDH exists 
as a type II membrane protein in osteosarcoma cells and its expression on cell surface is 
facilitating cell invasion by means of modulating cell adhesion to the ECM through 
interaction with Laminin. In total, these observations establish MTDH as a promising target 
for therapeutic interventions in metastatic osteosarcoma. The novel connection between 
MTDH and extracellular laminin also establishes a new paradigm for the function of MTDH 
in mediating tumor cell metastasis. 
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Biology of Osteosarcoma    
Osteosarcoma is the most common type of primary bone cancer in pediatric patients (1). 
It derives from primitive mesenchymal stem cells or osteoblasts and is characterized by the 
production of neoplastic osteoid or immature bone by tumor cells (2). Osteosarcoma occurs 
primarily in growing adolescents and young adults, with a peak incidence in the second 
decade of life. Consistent with its high incidence during puberty when bones grow rapidly, 
osteosarcoma usually arises from the metaphyseal regions of the long bones such as the distal 
femur and proximal tibia (3). As an exceedingly aggressive tumor, osteosarcoma has a high 
tendency to spread to distant organs in the body. The lung is the most frequent site for 
metastasis, followed by the bones (4). About 15-20% of patients present with overt lung 
metastases and nearly all of the remainder have micrometastatic disease at diagnosis (5, 6). 
The standard therapy consists of surgical removal of any resectable primary tumor and 
metastases, combined with 6-9 months of neoadjuvant and adjuvant chemotherapy. Current 
chemotherapy regimens include four agents: doxorubicin (adriamycin), cisplatin, high-dose 
methotrexate with leukovorin rescue, and ifosfamide (2). The addition of liposomal muramyl 
tripeptide phosphatidylethanolamine (mifamurtide) to therapeutic regimens demonstrated 
clinical benefit and has been approved by the European Union to treat high-grade, resectable, 
non-metastatic osteosarcoma (7). 
Although the modern multimodal therapy yields a survival of approximately 70% for 
patients without overt disease at diagnosis, the clinical outcome for metastatic osteosarcoma 
remains poor: fewer than 30% of patients presenting with metastases survive 5 years after 
initial diagnosis (8). The prognosis for patients with refractory or recurrent disease is even 
worse. Since current treatment options for osteosarcoma patients have very limited efficacy 
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against recurrent metastatic disease, most studies in this field have been focused on 
identifying key regulatory pathways and molecular events that mediate critical steps of 
metastasis.  
Essential pathways in osteosarcoma metastasis 
Migration and Invasion 
The process of tumor metastasis involves a complex cascade of events. The first step is 
to interact with and migrate through the extracellular matrix (ECM) and basement membrane 
that comprise barriers against invading cells. The pivotal role of matrix metalloproteinases 
(MMPs) including MMP-2 and MMP-9, as well as other proteases such as m-calpain, has 
been repetitively implicated in osteosarcoma metastasis (9-11). Previous studies also 
suggested that the Wnt/β-catenin pathway and Src signaling promote metastasis in 
osteosarcoma through modulation of tumor cell migratory ability (12). The Notch pathway, 
including its major components Notch receptor 1, 2, and the downstream target gene Hes1, 
has been recently identified to be important regulator of osteosarcoma invasion (13, 14).  
Survival in the bloodstream 
After tumor cell invade into the circulatory system, it is essential for disseminated 
tumor cells to acquire anoikis resistance in order to survive in the absence of intercellular 
adhesions and cell-ECM interactions. Several molecular mechanisms contribute to the 
evasion of anoikis in osteosarcoma, including overexpression of specific integrins, Focal 
adhesion kinase (FAK)-independent activation of PI3K/Akt signaling, activation of the Src, 
NFκB and Wnt/β-catenin pathways, and upregulation of anti-apoptotic genes of the BcL 
family (15).  
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Extravasation and adherence 
The next step of metastasis is to exit the circulatory vessels, invade into the distant 
organ, and adapt to the local microenvironment. The process of extravasation and metastatic 
colonization are primarily facilitated by proteinases and chemokines (16, 17). Commonly 
expressed chemokines in osteosarcoma include CXCR-3 and CXCR-4. Binding of these 
chemokines to their ligands, CXCL-9, -10, -11, and -12, which are abundantly expressed in 
the lung, not only mediate adherence of circulating tumor cells, but trigger other essential 
survival pathways as well (16, 18-24). Ezrin, a membrane-cytoskeleton linker protein 
overexpressed in variety of cancers, is associated with a higher risk of metastasis and poor 
survival in both animal models and pediatric patients with osteosarcoma (25-27). Previous 
studies suggested that ezrin facilitates adherence of metastatic osteosarcoma cells to lung 
tissues by mediating membrane organization and interactions between tumors cells and the 
lung microenvironment (28). Ezrin also promotes survival and proliferation of the newly 
arrived osteosarcoma cells in the lung through β4-integrin mediated activation of the 
PI3K/Akt and MAPK survival pathways (17, 22, 25, 26, 29). 
Dormancy 
It is frequently observed that osteosarcoma patients who present without radiographic 
evidence of metastasis at diagnosis develop metastatic relapse within 2-3 years after initial 
resection of the primary tumor (30, 31). This phenomenon is likely explained by the 
prolonged survival of single cells or micrometastases in the lung environment, which is 
defined as dormancy. When being triggered to start proliferating again, theses small lesions 
can quickly develop into gross metastases. Despite the clinical significance of tumor 
dormancy, the biological processes regulating dormancy and tumor outgrowth from dormant 
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state in osteosarcoma are still poorly understood. Previous studies indicated that tumor 
dormancy is controlled by overexpression of the anti-apoptotic protein Bcl-xL, α5β1-integrin 
mediated activation of NF-κB signaling, and the ratio between ERK and p38-MAPK proteins 
(17, 22, 32, 33). Since vascularization is an essential prerequisite for tumor expansion, 
metastatic cells usually increase the expression of anti-angiogenic proteins to suppress tumor 
outgrowth and maintain dormancy (34, 35). Recent research suggests that ECM, which is the 
source of various growth and survival signals, serves as an important mediator of tumor 
dormancy for metastatic cells (32, 35). Micrometastases usually remain in the dormant state 
in the absence of connection to the ECM in the lung environment, while proper anchorage to 
the ECM could activate dormant cells and stimulate them to proliferate via β1-integrin 
signaling. Additionally, dormancy has been shown to be related to a subpopulation of cancer 
stem-like cells (CSCs) which have the ability to self-renew and populate a growing tumor 
(36-40). With increased capacity for DNA repair and upregulation of anti-apoptotic proteins, 
CSCs could survive under metabolic and environmental stresses for a long time (41-46). 
Neovascularization 
Tumor growth and progression are often dependent on a sufficiency of nutrients and 
growth factors supplied by the blood vessels. Therefore, neovascularization and aberrant 
proliferation are prerequisites for the sustained expansion of metastatic lesions in the lung. 
Simultaneous upregulation of a number of pro-angiogenic factors like VEGF, FGF, HGF, 
PDGF, TGF- and Ang-1 and downregulation of anti-angiogenic factors such as 
thrombospondin-1, PEDF, and troponin I induce rapid neo-angiogenesis (47-51). Elevated 
expression of growth factor receptors and proteolytic enzymes, including EGFR, IGF-1R, 
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PDGFR, and MMPs, also contributes to survival and proliferation in metastatic osteosarcoma 
cells in the lung (52).  
Evasion of immune system 
Another important feature of the metastatic osteosarcoma cells that survive either in the 
circulatory system or at the sites of metastasis is the ability to evade the host immune 
surveillance. Downregulation of the cell surface receptor HLA class 1 prevents the tumor 
cells from being recognized by the host cytotoxic T-lymphocytes (52, 53). Metastatic 
osteosarcoma cells can also modulate the activity of the host immune system by inducing the 
expression of a group of immunosuppressive molecules such as IL-10 (22, 54). The Fas/FasL 
signaling pathway has also been implicated in immune evasion of osteosarcoma cells.  
Impaired downstream signaling of Fas/FasL pathway or downregulation of Fas expression on 
the surface of osteosarcoma cells inhibits Fas-induced cell death and prevents the activation 
of cytotoxic natural killer cells, resulting in an increase in metastatic potential. In support of 
this notion, patient-derived tumor specimens from osteosarcoma pulmonary metastases have 
been shown to be Fas-negative, and low Fas expression is associated with worse prognosis 
(55-59).  
In spite of tremendous past and ongoing efforts, our knowledge of the mechanisms 
underlying cell invasion and metastasis in osteosarcoma is still limited. Previous attempts to 
target pathways mentioned above have not demonstrated much clinical efficacy and there has 
been little improvement in the treatment of metastatic osteosarcoma over the last decade. To 
improve the clinical outcomes for patients with poor prognosis, it is urgent to find new 
therapeutic targets to block metastasis in this disease. We became interested in metadherin 
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(MTDH) because it has emerged in recent years as an oncogene that is critically involved in 
tumor pathogenesis and progression.  
Molecular Cloning of MTDH 
Metadherin (MTDH), also known as astrocyte elevated gene-1 (AEG1) and Lyric, was 
first identified in 2002 as a novel late response gene induced by HIV infection or treatment 
with TNF-or viral glycoprotein gp120 in primary human fetal astrocytes (60-62). In 2004, 
Brown and Ruoslahti named this protein MTDH as they identified its metastasis-promoting 
function in mouse breast cancer cell through an in vivo phage screening (63). The mouse-rat 
ortholog of MTDH was cloned in the same year as a tight junction protein that co-localizes 
with ZO-1 in rat prostate epithelial cells and encodes the lysine-rich CEACAM-1 co-isolated 
protein (Lyric) (64). Human MTDH gene contains 12 exons and 11 introns and is located at 
chromosome 8q22, a region that is frequently amplified in many cancers (60). The full-length 
MTDH cDNA contains 3611 bps (excluding the poly-A tail) and the human mRNA encodes 
a single-pass transmembrane protein consisting of 582 amino acid residues with a predicted 
molecular mass of 64 kDa (60, 65). Alternative splicing and posttranslational modifications 
of MTDH may lead to different molecular weights detected by western blotting, ranging 
from 20kDa to 80kDa (64, 66).  
MTDH structure and localization 
According to BLAST analysis of MTDH, the structure of this gene has no similarity to 
any currently known genes (64). Initial protein motif analyses failed to identify any known 
functional domains or motifs in MTDH except a putative transmembrane domain (TMD) and 
three nuclear localization signals (NLS) (60, 63, 64, 66). The highly hydrophobic TMD, 
which is further confirmed by multiple independent protein structure prediction approaches, 
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is localized very close to the N-terminal, between 51-72 amino acid residues (67). The 
function of the three NLSs, at the locations between 79-91, 432-451, and 561-580 amino acid 
residues, was further characterized by Thirkettle and colleagues (68). They found that the 
extended NLS-1 (78-130 a.a.) and NLS-3 (546-582 a.a.) are responsible for nucleolar and 
nuclear localization of MTDH respectively, and the NLS-2 (415-486 a.a.) ubiquitination 
directs the cytoplasmic distribution of MTDH. 
The subcellular localization and transmembrane orientation of this molecule have been 
a subject of great debate.  Initial characterization of MTDH suggested that it localizes 
predominantly to the cytoplasm, endoplasmic reticulum, perinuclear region, nucleus, and 
inside the nucleolus in various cell types (60, 66, 69). However, immunofluorescence 
detection and FACS analysis of non-permeabilized mouse mammary tumor cells revealed 
cell surface localization of MTDH (63). The orientation of cell surface MTDH remains 
controversial: while most investigators believe that MTDH has a Type Ib topology based on 
functional analyses and the C-terminal localization of the experimentally verified NLSs, 
Brown and Ruoslahti have demonstrated a type II orientation for MTDH in breast cancer 
cells and proposed a putative lung-homing domain (LHD) which they suggested mediates 
lung metastasis through interactions with lung endothelial cells (63, 66, 69). 
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Figure 1 
 
 
Figure 1. Schematic diagram of the full-length MTDH protein structure and topology 
on membrane. The numbers denote amino acid positions. TMD: transmembrane domain; 
NLS: nuclear localization signal; and LHD: lung homing domain.  
 
 
MTDH in cancer 
MTDH is ubiquitously expressed in all human normal tissues at varying levels (60). 
However, numerous studies over the past decade have demonstrated that MTDH expression 
is significantly upregulated in many types of solid tumors including glioma, 
oligodendroglioma, neuroblastoma, melanoma, brain, head and neck, breast, prostate, 
esophageal, lung, gastric, renal, liver, and colorectal cancer when compared with normal 
tissues (60, 63, 65, 70-84). Consistent with the high incidence of MTDH overexpression in 
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cancer, recent clinical studies have provided convincing evidence of an association between 
high MTDH expression level and advanced tumor stage as well as poor patient prognosis (68, 
70, 78, 80-83). These observations strongly suggest that MTDH could be employed as a 
powerful diagnostic or prognostic marker in a variety of cancer types. 
In parallel with evaluation of MTDH as a biomarker for cancer, mounting evidence 
from functional studies indicates a pivotal role of MTDH in diverse aspects of tumor 
malignancy including aberrant proliferation, angiogenesis, invasion, metastasis, and 
chemoresistance (69, 77, 85). In addition to its unique ability to modulate gene expression 
changes that are common in cancer, MTDH promotes tumor progression through activation 
and integration of multiple pro-tumorigenic signal transduction pathways (65, 67). Ras 
signaling increases MTDH expression (86), which subsequently promotes cancer cell growth, 
survival, and invasion through the activation of PI3K/Akt (69), NF-κB (87, 88), and Wnt/β-
catenin pathways (77). MTDH-induced activation of PI3K/Akt signaling protects cells from 
apoptosis and facilitates angiogenesis (85, 89). By activating NFκB and its downstream 
targets, MTDH increases proliferation, angiogenesis, inflammation, and invasion in tumor 
cells (16, 88). MTDH could also alter expression of a group of genes involved in invasion, 
chemoresistance, senescence, and angiogenesis through Wnt/β-catenin pathway (78) 
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Figure 2 
 
Figure 2. MTDH promotes tumor progression through the integration of multiple 
signaling pathways. Oncogenic Ha-Ras increases MTDH expression through the activation 
of the PI3K/Akt pathway, which phosphorylates and inactivates GSK3β, and subsequently 
enhances the stabilization and binding of c-Myc to the MTDH promoter. Activation of NFκB 
signaling is partially mediated by the direct interaction of MTDH with p65 and CBP. MTDH 
activates the Wnt/β-catenin pathway through increasing the activity of MAPK kinases ERK 
and p38, which phosphorylates GSK3β and stabilized β-catenin. Furthermore, MTDH 
increases the expression of LEF-1, a transcriptional cofactor for β-catenin. The important role 
of MTDH in broad spectrum chemoresistance is mediated by many downstream genes that 
promote the resistance to multiple chemotherapeutic agents. Reprinted from Hu G et al. Clin 
Cancer Res 2009;15:(5615-5620) with permission from American Association for Cancer 
Research. 
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MTDH and metastasis  
As an important mediator of tumor development and progression, the invasion-
promoting function of MTDH has been confirmed by multiple studies in various types of 
aggressive cancer including glioma, neuroblastoma, prostate cancer, breast cancer, 
hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma, and colorectal 
carcinoma (63, 70, 73, 74, 78, 84, 90). Upregulation of MTDH leads to elevated expression 
of adhesion molecules, which facilitate both the extravasation and intravasation processes of 
metastasis. A recent study comparing metastatic potential of HCC cell lines with different 
MTDH expression displayed that cells with higher endogenous MTDH levels have better 
adhesive ability to microvascular endothelial cells than those with relatively lower MTDH 
expression (91). Additionally, MTDH-induced activation and secretion of MMPs, especially 
MMP1, MMP2 and MMP9, have been shown to promote metastasis through remodeling and 
degradation of ECM (70, 71, 84). In cancers of epithelial origin such as breast cancer and 
HCC, MTDH could enhance metastatic spread of tumor cells by inducing the epithelial-
mesenchymal transition (EMT) process (92, 93).  
Another important finding concerning the function of MTDH in metastasis is the 
identification of the putative extracellular lung-homing domain through a phage display 
experiment conducted in the breast cancer mouse model. It has been shown that 
overexpression of MTDH in human embryonic kidney cells enhances their localization to 
lung vasculatures. Neutralizing antibodies targeting this specific domain of MTDH displayed 
comparable inhibition of experimental pulmonary metastasis as siRNA-mediated MTDH 
knockdown in breast cancer cells. Based on these observations, it was postulated that MTDH 
favorably promotes pulmonary metastasis as it detects and binds to an unknown marker that 
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is primarily expressed on the surface of lung endothelial cells. However, the hypothesis that 
MTDH has a binding preference for the lung vascular bed remains questionable. Recent 
studies have demonstrated that MTDH not only promotes lung metastasis, but also enhances 
metastasis to other organs, such as the bone and brain in breast cancer, and liver in colorectal 
cancer (65, 94). To date, the molecular mechanisms of MTDH binding to endothelium 
remain elusive.  
The role of MTDH in osteosarcoma 
The first study to characterize the expression status of MTDH in osteosarcoma was 
conducted by Wang and colleagues in 2011(95). They performed immunohistochemical 
staining to examine the MTDH expression level in 82 paraffin-embedded surgical specimens, 
including 62 osteosarcoma samples and 20 normal bone tissues from patients who had 
received neoadjuvant chemotherapy. They found that MTDH was overexpressed in the 
majority of osteosarcoma samples assessed while MTDH expression was barely detectable in 
normal bone tissues. Spearman correlation analysis based on IHC staining score of theses 
specimens indicated that MTDH overexpression is strongly associated with clinical stages, 
classification, metastasis, and differentiation. Moreover, the average survival time in the low 
MTDH expression group was remarkably longer than that in high MTDH expression 
group. The only other report about the function of MTDH in osteosarcoma was focused on 
how MTDH mediates chemoresistance (96). It has been shown that MTDH confers 
chemoresistance in osteosarcoma cells by regulating ET-1/ETAR signaling pathway in a 
PI3K-dependent manner. Due to the lack of knowledge about the role of MTDH in 
osteosarcoma metastasis, we decided to focus our efforts on exploring this research topic. 
 
 14 
 
Goal of dissertation 
Osteosarcoma is the most common bone malignancy, causing significant morbidity and 
mortality in teenagers and young adults. With current treatment regimens combining 
chemotherapy and surgery, osteosarcoma patients with localized disease have a survival rate 
that approaches 70%. However, the clinical outcome for metastatic osteosarcoma remains 
poor. For patients who suffer from this fatal disease, a better understanding of how their 
cancer metastasizes will lead to novel therapeutic approaches that will significantly prolong 
their survival and improve the quality of their lives. To address this challenge, it is critical to 
identify and characterize promising proteins and key pathways responsible for osteosarcoma 
progression and metastasis and to develop their specific inhibitors. 
Over the past 10 years, numerous studies have consistently demonstrated that high 
expression of MTDH is associated with increased tumor aggressiveness, metastasis, and 
decreased patient survival in a variety of human solid tumors. These observations establish 
MTDH as a promising target for therapeutic interventions. It will be important to know 
which tumors might benefit from such treatments. To date, however, very few studies have 
examined the functional role of MTDH in osteosarcoma and our knowledge about how 
MTDH expression affects osteosarcoma metastasis is very limited. The first goal of our 
research was to confirm the expression status of MTDH in osteosarcoma and to assess its 
impact on patient survival. Next, we wanted determine the sub-cellular localization and 
transmembrane orientation of MTDH in osteosarcoma. We planned to use both in vitro and 
in vivo approaches to explore the biologic function(s) of MTDH in osteosarcoma progression 
and metastasis. Further, we wished to elucidate the mechanism(s) underlying the metastasis-
promoting activity of MTDH, which are very likely to have impacts beyond osteosarcoma.  
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Prior work on MTDH mechanisms have largely focused on its direct involvement in 
classical oncogenic pathways so that protein-level interactions have been scarcely studied. 
Currently, the means by which MTDH enhances cancer metastasis remain unclear. As 
mentioned earlier, Brown and Ruoslahti proposed that the cell surface MTDH contains an 
extracellular lung-homing domain which facilitates lung metastasis by binding to an 
unknown ligand on pulmonary endothelial cells (63). However, our preliminary data in a 
colon cancer cell line indicated that MTDH might regulate metastasis by modulating cell 
attachment to ECM components, which is completely independent of endothelial cell binding. 
One major goal of this research is to identify the potential MTDH-interacting protein(s) in 
ECM. Characterization of the association between MTDH and ECM component will help us 
gain better understanding of the metastasis-promoting function of MTDH and at the same 
time provide novel target(s) for developing anti-metastasis therapy. More importantly, the 
new findings will be applicable to a broad panel of invasive solid tumors with MTDH 
overexpression and therefore would benefit more patients.  
Combining our preliminary results and current knowledge about the functions of 
MTDH in cancer, we hypothesize that MTDH overexpression promotes osteosarcoma cell 
migration and invasion in response to recognition of non-cellular protein component of ECM 
(Figure 3).  
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Figure 3 
 
Figure 3. Hypothesis: MTDH interacts with specific extracellular ECM component to 
facilitate tumor cell invasion and migration in osteosarcoma. 
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Chapter 2. Materials and Methods 
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Cell lines and reagents 
Human osteosarcoma cell lines HOS, CCHD, SAOS2, LM7, SJSA, MG63 were 
maintained in High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) 
supplemented with L-glutamine and 10% Fetal Bovine Serum (FBS) (Hyclone) in a 
humidified atmosphere at 37°C with 5% CO2. The established osteosarcoma cell lines HOS, 
SAOS2, SJSA, and MG63 are available from ATCC. LM7, a subline of SAOS2 with high 
metastatic potential, was developed by repeated passaging of SAOS2 cells through 
pulmonary metastases in nude mice (97). CCHD is a stable OS cell line derived from pre-
treatment biopsy of a proximal femur lesion in an 18-year-old male patient who presented 
with pulmonary metastases at M. D. Anderson Children’s Cancer Hospital. The human fetal 
osteoblastic cell line hFOB  (ATCC) was cultured at 34°C with 5% CO2 in a 1:1 mixture of 
phenol-free Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium with 2.5 mM L-
glutamine (DMEM-F12) (Invitrogen), supplemented with 10% FBS and 0.3 mg/ml G418.  
Patient Samples 
Formalin-fixed, paraffin-embedded tissue blocks (FFPE) of osteosarcoma cases were 
obtained from the files of the Department of Pathology, University of Michigan Medical 
Center, Ann Arbor, MI. The University of Michigan Institutional Review Board provided a 
waiver of informed consent to obtain these samples. After pathological review, a tissue 
microarray was constructed from the most representative area using the methodology of 
Nocito et al. (98). Each case was represented by two 1 mm or three 0.6 mm diameter cores, 
obtained from the most representative, non-necrotic area of the tumor. The osteosarcoma 
TMA containing primary tumor specimens from 49 patients and metastatic tumor specimens 
from 24 patients was used to evaluate the expression level of MTDH in osteosarcoma with 
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immunohistochemistry (IHC). All specimens were reviewed by Dr. Wei-Lien Wang, an 
experienced sarcoma pathologist at M.D. Anderson Cancer Center. Scoring of the tumor 
samples was based on IHC staining intensity (as shown in Fig.7), and the intensity of the 
signal was classified as 0 (no expression), 1 (weak expression), 2 (moderate expression) or 3 
(strong expression).  
Western blotting 
Whole cell lysates from a panel of human osteosarcoma cell lines and normal human 
osteoblast cells were prepared as follows: Cells were detached from the culture plates with 
the aid of cell scrapers and washed with cold PBS. After 10-minute centrifugation at 13,000 
rpm, cell pellets were resuspended and incubated in cold lysis buffer (25mM Tris-HCl pH 7.4, 
150mM NaCl, 1mM EDTA, 1% NP-40 and 5% glycerol) with protease inhibitor cocktail 
tablets (Roche Diagnostics) and phosphatase inhibitor cocktail 2 (Sigma) at 4°C for 20 
minutes. Lysates were collected after being centrifuged at 13,000 rpm for 10 minutes. The 
protein concentrations were determined using the bicinchoninic acid (BCA) assay (Thermo 
Scientific). Whole-cell lysates were separated by SDS-PAGE on a 10% polyacrylamide gel 
and transferred to nitrocellulose membrane following standard procedures. To detect MTDH 
protein level, membrane was probed with rabbit-anti-MTDH antibody (1:1,000; Sigma-
Aldrich), followed by horseradish peroxidase-conjugated anti-rabbit IgG (1:2,000; GE 
Healthcare). Beta-actin (Sigma-Aldrich) was probed as a loading control. Chemiluminescent 
signal was detected using Pierce ECL western blotting substrate (Thermo Scientific). 
Real-time quantitative PCR 
Total RNA was extracted from osteosarcoma cells with the RNeasy Mini Kit (Qiagen). 
cDNA was made using the Omniscript Reverse Transcriptase Kit (Qiagen) with oligo-dTs 
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(Invitrogen) according to the manufacturer's instruction. Real-time PCR analysis was 
performed by the iCycler iQ quantitative PCR system (Bio-Rad) using SYBR Green PCR 
Master Mix (Bio-Rad) following the protocol of the manufacturer. The primers used were as 
follows: MTDH (Forward) 5’-CACTGTCAATGGAGGAGGCT-3’; MTDH (Reverse) 5’-
TGAACGGTCACTCCAACTCC-3’; GAPDH (Forward) 5’-
GCATCCTGGGCTACACTGAG-3’; GAPDH (Reverse) 5’-
CCACCACCCTGTTGCTGTAG-3’. Expression data were normalized to GAPDH 
expression in each sample and were analyzed according to the 2-ΔΔ Ct method. The fold 
changes in gene expression were calculated relative to the mRNA level of the control cell 
line hFOB. 
Flow cytometry  
To measure the cell surface expression of MDTH, a panel of osteosarcoma cells were 
detached from culture plates by enzyme-free cell dissociation buffer (Invitrogen) and washed 
with cold PBS/1% bovine serum albumin (Fisher Scientific).  The cells were incubated with 
normal rabbit IgG (1:100; Millipore) or rabbit anti-MTDH antibody (1:100; Sigma-Aldrich) 
on ice for 1 hour. The cells were then washed with PBS/1% BSA three times and blocked 
with PBS/1% BSA containing 10% goat serum. Cells were then incubated with PE-
conjugated anti-rabbit IgG (1:50; Molecular Probes) on ice for 30 minutes and washed as 
above. Expression was then assessed using a FACSCaliber flow cytometer (BD Biosciences) 
and analyzed with Flowjo software (Tree Star Inc). 
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Retroviral transduction 
To silence human MTDH gene, four pGFP-V-RS shRNA retroviral constructs 
(Origene) were used to generate 29-mer short hairpin RNAs (shRNA) targeting MTDH. The 
shRNA sequences for MTDH are:  
SH-3:  5’-GAAATCAAAGTCAGATGCTAAAGCAGTGC-3’  
SH-4:  5’-TGCTGAGCCAGTTTCTCAGTCTACCACTT-3’ 
SH-5:  5’-CATCACAGTTACCACCGAGCAACTTACAA-3’ 
SH-6:  5’-GGTGATTCTCATCTAAATGTTCAAGTTAG-3’  
To generate retrovirus, Phoenix-Ampho cells (ATCC) were seeded in 6-well plates at a 
density of 1 million cells per well without antibiotics. After 12 hours, FuGENE 6 transfection 
reagent (Roche) was diluted in serum-free DMEM to generate 100 µl solution (90 µL 
DMEM and 10 µL FuGENE 6). After a 5-minute incubation, 3 µg of pGFP-V-RS vectors 
containing MTDH shRNA or scrambled control sequence were added to the diluted FuGENE 
6 transfection reagents and co-incubated at room temperature for 30 minutes. Next, the 
transfection components were added to the cells and the culture plates were returned to the 
incubator. The transfection complex was removed and replaced with fresh DMEM at 12 
hours after initial transfection. After 24 hours, medium containing virus was collected and 
centrifuged at 1500 rpm for 5 minutes. 2 ml of viral supernatant and 8 µg/ml Polybrene 
(Sigma) were combined and added to HOS and CCHD cells. The plates were centrifuged at 
2500 rpm for 50 minutes and then incubated at 34°C overnight. Viral medium was replaced 
by fresh medium and cells were returned to standard culture conditions. After being selected 
for puromycin resistance for 7 days, the stably transduced cells were analyzed by western 
blot for MTDH protein expression, and knockdown was confirmed by densitometric analysis 
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(Image J Processing Software, NIH). Cells transduced with SH-4 and SH-6 displayed the 
highest MTDH knock-down efficiency, and therefore were used in parallel with cells 
transduced with scrambled control plasmid in subsequent assays as indicated in individual 
experiments. 
Cell proliferation assay 
Cells were seeded in triplicate into 6-well plates at the density of 2x104 and 5x104 
cells/well respectively for HOS and CCHD cell lines. The number of viable cells was 
counted after 2, 4, and 6 days of culture by using an automated Vi-Cell Analyzer (Beckman 
Coulter). Cells were prepared as follows: medium was removed from the culture plates and 
the cells were rinsed with PBS to remove the dead cells and debris. Cells were co-incubated 
with 0.5 ml of 0.01 M HEPES/0.015 M MgCl2 buffer at room temperature for 5 minutes. 
Next, 50 µl of 0.132 M Bretol (Ethylhexadecyldimethylammonium bromide) with 0.525 M 
glacial acetic acid was added to the cells and the culture plates were agitated for 10 minutes 
at room temperature. Cells were then fixed by the fixative solution (0.9% NaCl and 0.5% 
formalin).  2 ml of the solution containing cell nuclei was transferred into an autosampler cup 
for further processing by the automated Vi-Cell Analyzer. 
Matrigel invasion assay 
The invasive ability of osteosarcoma cells was evaluated by using 24-well BD BioCoat 
Matrigel invasion chambers with 8-μm pore size (BD Biosciences). Briefly, 2x104 or 5x104 
cells suspended in 300 µl of serum-free DMEM medium were seeded in triplicate into the 
upper chamber of the system. The lower chamber contained 750 µl DMEM medium with 10% 
FBS as a chemoattractant. In the antibody-blocking experiments, rabbit-anti- MTDH 
antibody (Simga-Aldrich) or normal rabbit IgG (Millipore) were used at a final concentration 
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of 7.5 µg/ml to treat HOS and CCHD cells during the incubation period. After 48h 
incubation at 37°C, the migrated cells were fixed, stained with Hema-3 (Fisher Diagnostics), 
and counted under a microscope at 100-fold magnification. 
Cell migration assay 
In vitro cell migration was performed in the 24-well Corning Transwell polycarbonate 
membrane cell culture inserts with 8-μm pore size (Corning). The 3x104 cells  suspended in 
100 μl serum-free DMEM were seeded into the upper part of each chamber, whereas the 
lower compartments were filled with 600 μl of DMEM with 10% FBS. Normal rabbit IgG 
(Millipore) and rabbit-anti-MTDH antibody (Sigma-Aldrich) at a final concentration of 7.5 
µg/ml were used in the antibody-blocking experiments. After incubation for 24 h at 37°C, the 
migrated cells were fixed, stained with Hema-3, and counted under a microscope at 100-fold 
magnification. 
Animal Model 
To be sure that in vivo experiments were not compromised by growth of contaminating 
non-transduced cells, clones were made from the MTDH shRNA #4 and scrambled control 
CCHD cells described above by limiting dilution and visual confirmation of clonality.  
Several were tested, and a clone whose growth characteristics matched the bulk population 
most closely was chosen for in vivo experiments.  These cells were then retrovirally labeled 
with firefly luciferase as described (99). Luciferase-labeled CCHD cells (1×106 cells 
suspended in 15μl of sterile PBS) were injected into the right tibia of 6-week-old 
NOD/SCID/IL2Rγ-deficient mice (Jackson Laboratories). Primary tumor growth and 
development of metastasis were monitored weekly through noninvasive bioluminescent 
imaging using an IVIS 100 animal imaging system (Xenogen).  Mice were sacrificed at 6 
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weeks after inoculation, the lungs inflated with 10% formaldehyde via transtracheal injection, 
and the primary tumors and lungs fixed in formalin and embedded in paraffin.  Five micron 
sections were mounted on glass slides for analysis, and H&E staining was performed by our 
core laboratory. Metastatic nodules in lungs were quantified by direct microscopic 
visualization and counting of a single lung section and confirmed by an experienced sarcoma 
pathologist. All animal experiments were approved by the Institutional Animal Care and Use 
Committee. 
Immunohistochemistry 
Immunohistochemistry was performed using formalin-fixed, paraffin-embedded tissue 
sections. Heat Induced Epitope Retrieval (HIER) was performed on paraffin-embedded 
tissues with 0.1M Sodium Citrate buffer, pH 6.0. After being blocked with 4% fish gelatin in 
PBS for 20min, sections were incubated with rabbit-anti-MTDH antibody (1:300; Sigma-
Aldrich) in a humidified chamber at 4°C overnight.  Slides were incubated with rabbit-on-
rodent HRP-polymer (Biocare) or Mach 4 HRP polymer (Biocare) for 30min at room 
temperature and staining was developed using DAB followed by Hematoxylin 
counterstaining. Images were analyzed using a Leica light microscope. 
Immunofluorescence 
Osteosarcoma cells were seeded in 4-well Lab-Tek chamber slides (Nunc) at a density 
of 1x105 cells per well in standard tissue culture conditions. Medium was removed after 12 
hours and cells were fixed in -20°C acetone and 1:1 acetone and chloroform mixture for 5 
minutes each.  Cells were blocked with 4% fish gelatin in PBS and incubated with rabbit-
anti-MTDH antibody (1:300; Sigma-Aldrich) in a humidified chamber at 4°C overnight.  
Slides were incubated with Alexa 488-labeled anti-rabbit secondary antibody (1:1,000, 
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Molecular Probes) for 1h and nuclei were counterstained with Hoechst (1:10,000) for 5 
minutes. Slides were mounted with anti-fade mounting media (glycerol/PBS containing N-
propyl gallate) and a coverslip. Images were taken on a Nikon fluorescence microscope. 
Cell adhesion assay 
Cells were harvested, suspended in serum-free DMEM medium, and seeded in 
triplicates (2x104 cells/well) onto 96-well plates pre-coated with Matrigel, Fibronectin, 
Laminin, or Collagen-type IV (BD Biosciences).  In the antibody-blocking experiments, 
rabbit-anti- MTDH antibody (Sigma-Aldrich) or normal rabbit IgG (Millipore) were used at a 
final concentration of 7.5 µg/ml to treat HOS and CCHD cells during the period of co-
incubation. After 1h incubation at 37°C in a humidified incubator containing 5% CO2, 
unattached cells were removed by rinsing three times with PBS, Meanwhile, the input control 
groups were left unwashed and the plates were centrifuged at 1300 rpm for 3min to force the 
cells onto the bottom of the well. The remaining attached cells were fixed and stained with 
Hema-3 (Fisher Diagnostics). The number of cells from three different fields of each well 
was counted at 10X magnification. The percentage of adhesion was calculated by dividing 
the average cell number of PBS-washed group with that of the respective input control group.  
Co-Immunoprecipitation 
To investigate whether MTDH interacts with extracellular Laminin through formation 
of a protein complex, HOS cells were cultured under standard conditions until they reached 
80-90% confluence and then treated with matrigel (1:100 dilutions) for 1h at 37°C. The cells 
were then thoroughly washed with PBS to remove any unbound ECM components. Whole-
cell lysates were made and subjected to co-immunoprecipitation with anti-MTDH antibody 
(Sigma-Aldrich), anti-Laminin antibody (Abcam), or normal IgG (Millipore) following 
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manufacturer’s instructions. The precipitated proteins were then transferred to nitrocellulose 
membrane and probed with anti-MTDH, anti-Laminin, and anti-Fibronectin (Abcam) 
antibodies. 
Statistical analyses 
Triplicate samples were analyzed in each assay, and all experiments were conducted at 
least three times.  Data are represented as mean ± standard error of mean (SEM). Statistical 
analysis was performed using two-tailed Student’s t test (GraphPad Software Inc). Log-rank 
test was used for assessment of survival curves. A p-value of <0.05 was considered 
statistically significant in all cases.  
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Chapter 3: Elevated MTDH expression is associated with metastasis and poor outcome 
in several cancers including osteosarcoma 
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Rationale 
As mentioned earlier, MTDH has been found to be widely upregulated in many types 
of aggressive solid tumors and is often associated with poor survival (68, 70, 78, 80-83). 
Accumulating evidence from functional studies of MTDH confirmed the importance of this 
protein in many aspects of tumor growth and progression including metastasis (69, 77, 85). 
To determine whether MTDH is involved in promoting metastasis in aggressive human 
tumors, we started with analyzing the expression patterns of MTDH in microarray databases 
of various cancer patients. We hypothesized that MTDH expression in distant metastases is 
greater than that in primary tumors, and MTDH overexpression correlates with higher risk 
for metastasis and worse survival in patients.  
To obtain the relevant clinical information that contains survival and metastasis data, 
we used publicly available cancer microarray databases (Oncomine, and R2: microarray 
analysis and visualization platform) and osteosarcoma tissue microarray (a kind gift from Dr. 
Dafydd G. Thomas, Department of pathology, the University of Michigan Hospitals and 
Clinics, Ann Arbor, Michigan) to assess the correlation between MTDH expression and 
clinical outcome in patients with breast cancer, prostate cancer, melanoma, and osteosarcoma. 
Since MTDH has been rarely studied in osteosarcoma and the role of MTDH in 
osteosarcoma metastasis remains unclear, we have concentrated our efforts in studying this 
disease. 
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Results 
High MTDH expression is associated with metastasis and poor survival in multiple 
aggressive human cancers 
Analysis of MTDH mRNA levels in primary and metastatic lesions in two melanoma 
datasets and one prostate cancer dataset revealed that metastatic lesions exhibited 
significantly higher level of MTDH than primary tumors (1.8 fold in Haqq Melanoma, 
p=0.005; 1.7 fold in Xu Melanoma, p=2.19E-6; and 3.9 fold in Chandran Prostate, p=1.75E-
10) (Figure 4). To determine whether MTDH expression is predictive of distant metastatic 
relapse, we compared the MTDH mRNA level in primary tumor samples obtained from 
patients who developed metastasis during the 3-year follow-up period versus those who did 
not. Significantly higher level of MTDH (4.1 fold difference, p=1.25E-5) was observed in 
patients who progressed to metastatic relapse, indicating that MTDH overexpression is 
closely related to high metastatic potential of melanoma (Figure 5). In three independent 
datasets, we further explored the relationship between MTDH expression and clinical 
outcome in patients with melanoma and breast cancer (Figure 6). Analysis of stage III 
melanoma patient data indicated that MTDH overexpression is correlated with shorter 
survival from metastasis. Significantly shortened overall survival and metastasis-free survival 
were observed in the high MTDH-expressing group as compared to the low MTDH-
expressing group in breast cancer patients. These results imply that MTDH is overexpressed 
in metastasis and may serve as an important prognostic marker of metastasis risk and survival 
for cancer patients. 
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Figure 4 
  
 
Figure 4. MTDH expression is elevated in metastatic lesions. Comparison of MTDH 
mRNA levels between unpaired primary tumors and metastatic lesions was performed in two 
independent melanoma datasets (5 primary samples and 15 metastatic samples in Haqq 
Melanoma dataset; 31 primary samples and 52 metastatic samples in Xu Melanoma dataset) 
and one prostate cancer dataset (10 primary samples and 21 metastatic samples). All datasets 
were accessed through the Oncomine Research Edition (https://www.oncomine.org).  
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Figure 5 
 
                      
 
 
Figure 5. MTDH overexpression is associated with high incidence of metastatic relapse. 
Comparison of MTDH mRNA expression levels between the patients with and without 
newly developed metastatic lesions during follow-up period was performed in Laurent 
melanoma dataset (19 samples total). Melanoma dataset was accessed through the Oncomine 
Research Edition (https://www.oncomine.org). 
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Figure 6 
 
 
 
 
Figure 6. High MTDH expression is associated with poor clinical outcome in melanoma 
and breast cancer patients. Kaplan-Meier survival analysis was used to assess the 
prognostic significance of MTDH in overall survival and metastasis-free survival of patients 
with melanoma and breast cancer. Melanoma and breast cancer datasets were accessed 
through the Oncomine Research Edition (https://www.oncomine.org). The log-rank test was 
used to calculate the p value. 
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MTDH expression in patient-derived osteosarcoma samples 
To evaluate the expression of MTDH in primary and metastatic lesions of 
osteosarcoma, a tissue microarray containing 49 primary tumor samples and 24 metastatic 
tumor samples were examined by IHC staining with anti-MTDH antibody. MTDH 
expression level was reported to be very low in normal bone tissues (95), but we observed 
substantial MTDH staining in patient-derived osteosarcoma samples (Figure 7). Among the 
49 primary tumor samples, 18/49 (37%) had no detectable MTDH, 17/49 (35%) displayed 
weakly positive staining, 10/49 (20%) were moderately positive, and the remaining 4 
samples (8%) had strong MTDH expression. In comparison, the staining intensity for MTDH 
was more abundant in metastatic tumor samples:  only 3/24 (12%) scored negative, 9/24 
(37%) were weakly positive, 10/24 (42%) were moderately positive and 2/24 (9%) displayed 
strong staining of MTDH (Table 1).  
IHC analysis of the MTDH expression levels in 9 pairs of matched primary 
osteosarcoma and metastases revealed that metastatic lesions had a significant 2.5 fold 
increase in average MTDH staining intensity in comparison with their primary tumor 
counterparts (p<0.05, Figure 8). Of the 9 patients, 7 patients had increased MTDH expression 
from primary to metastatic tumor, 1 patient had equal MTDH expression in primary and 
metastatic tumor, 1 patient displayed decreased MTDH in metastatic lesions. Taken together, 
these observations suggested that MTDH is overexpressed in the majority of osteosarcoma 
samples. In addition, increased MTDH expression could be detected in metastatic lesions 
compared with primary tumors. 
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Figure 7 
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Figure 7. MTDH is highly expressed in osteosarcoma patient samples. Representative 
MTDH immunohistochemical staining images of human osteosarcoma tissue microarray 
were taken using a Leica light microscope. Stacked histogram displayed here represents the 
proportion of samples in which MTDH expression was negative, weak, moderate or strong, 
per the scale shown in the top panel. All specimens were reviewed by an experienced 
sarcoma pathologist at M.D. Anderson Cancer Center.  
 
 
Table 1 
MTDH Expression 
Expression Score 
n (%) 
Primary Tumor Metastatic Lesion 
0 18 (37%) 3 (12%) 
1 17 (35%) 9 (37%) 
2 10 (20%) 10 (42%) 
3 4 (8%) 2 (9%) 
Total 49 (100%) 24 (100%) 
 
Table 1. Summary of osteosarcoma tissue microarray immunostaining data. Expression 
score: 0-negative expression, 1-weakly positive expression, 2-moderately positive expression, 
3-strongly positive expression. 
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Figure 8 
                           
Figure 8. MTDH expression increases from primary to metastatic tumors in 
osteosarcoma. Comparison of MTDH expression between primary tumors and distant 
metastatic lesions was conducted on paired samples obtained from 9 osteosarcoma patients. 
Scoring of the tumor samples was based on IHC staining intensity. The expression score was 
classified as 0 (negative expression), 1 (weak expression), 2 (moderate expression) or 3 
(strong expression).  
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Table 2 
MTDH Expression 
Patient ID 
Expression Score 
Primary Tumor Metastatic Lesion 
1 0 1 
2 0 3 
3 1 2 
4 1 1 
5 0 1 
6 3 2 
7 1 2 
8 0 2 
9 0 1 
Mean Score 0.67 1.67 
 
Table 2. Comparison of MTDH expression scores in paired samples from the 
osteosarcoma tissue microarray. Expression score: 0-negative expression, 1-weakly 
positive expression, 2-moderately positive expression, 3-strongly positive expression. Red 
number represents increased MTDH expression score in metastatic lesion; black number 
represents equal MTDH expression score in metastatic lesion; blue number represents 
decreased MTDH expression score in metastatic lesion. 
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MTDH overexpression correlates with metastasis and poor survival in osteosarcoma 
patients 
To further assess the correlation between MTDH expression and clinical outcomes of 
osteosarcoma patients, Kaplan-Meier survival analyses were performed on pretreatment 
diagnostic biopsies of 88 high-grade osteosarcoma patients. 19 samples from patients who 
presented with metastasis at diagnosis were excluded from the analysis. The other 71 samples 
were categorized into high (n=42) and low (n=29) MTDH-expressing groups according to 
MTDH gene expression levels. Our results revealed that patients with high MTDH 
expression had significantly poorer metastasis-free survival (p < 0.05) and relatively 
decreased overall survival (p = 0.10) rate compared with the low MTDH-expressing group 
(Figure 9). In this respect, MTDH may serve as an important prognostic biomarker of 
metastasis risk and survival for patients with osteosarcoma. With the available online 
resources, we also compared MTDH expression in tumor samples from patients who 
developed metastatic disease within 5 years versus those who did not within the same time 
frame. MTDH level was found to be significantly higher in the patients who developed 
metastatic relapse within 5 years after initial diagnosis of osteosarcoma (Figure 10). 
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Figure 9 
 
 
Figure 9. High MTDH expression correlates with worse clinical outcome in genomic 
screen of high-grade osteosarcoma samples. Kaplan-Meier survival estimates of 
metastasis-free and overall survival were generated from the Kuijjer Mixed Osteosarcoma 
Database - Cleton-Jansen Lab. The dataset was accessed through the R2: microarray analysis 
and visualization platform (http://r2.amc.nl). The log-rank test was used to calculate 
the p value. 
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Figure 10 
            
 
Figure 10. MTDH overexpression predicts high risk of metastasis in osteosarcoma. 
Comparison of the MTDH expression in primary tumors between patients with and without 
newly developed metastatic disease within 5 years after diagnosis was performed in the 
Kuijjer osteosarcoma dataset (53 samples total). The dataset was accessed through the R2: 
microarray analysis and visualization platform (http://r2.amc.nl). 
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Summary 
By comparing MTDH expression between primary and metastatic tumor samples in 
melanoma, prostate cancer, and osteosarcoma, we confirmed that MTDH is upregulated 
during the metastatic process. As shown in Figure 5 and 10, MTDH overexpression has been 
associated with higher risk of metastatic relapse in melanoma and osteosarcoma. Our 
survival analysis in Figure 6 and 9 further revealed that high MTDH expression accelerates 
tumor progression and predicts shorter overall and metastasis-free survival in several 
aggressive cancers including osteosarcoma. These observations are consistent with previous 
findings that MTDH is a powerful marker for tumor aggressiveness and a predictor for poor 
patient prognosis (68, 70, 78, 80-83). As depicted in Figure 8, the significant increase in 
MTDH expression from primary to metastatic tumors in the same patient spurred our interest 
in understanding the mechanisms by which MTDH causes more aggressive disease. All the 
clinical evidence described in this chapter supported the significance of MTDH 
overexpression in osteosarcoma metastasis and warranted further exploration in this disease 
model. 
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Chapter 4. MTDH is overexpressed on osteosarcoma cell surface as a type II 
transmembrane protein  
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Rationale 
 A strong correlation between high MTDH expression and distant metastasis has been 
implicated in two independent osteosarcoma clinical datasets presented in Chapter 3. This 
finding triggered our interest to further explore the function(s) of MTDH in osteosarcoma, 
and particularly in osteosarcoma metastasis. To continue the functional studies of MTDH in 
osteosarcoma cell models, we had to examine the expression status of MTDH in each of the 
osteosarcoma cell lines included in this study through western blotting and real-time 
quantitative PCR.  
Another important goal of this chapter is to investigate the distribution of MTDH 
protein in osteosarcoma cells through immunofluorescence microscopy because the 
subcellular localization of a protein is tightly linked to its function. To date, there is still great 
uncertainty and controversy over the potential localization of MTDH in cancer cells as some 
studies showed cytoplasmic and perinuclear localizations of MTDH while others suggested 
that MTDH primarily expressed inside the nucleus (60, 66, 69). In 2004, Brown and 
Ruoslahti provided the first and only evidence that supports the cell-surface localization of 
MTDH in a study about the role of MTDH in breast cancer metastasis (63). Considering the 
significance of cell surface proteins in cancer, we proposed that MTDH is abundantly 
expressed on the surface of osteosarcoma cells. Moreover, we wanted to use flow cytometry 
to determine the transmembrane topology of MTDH in osteosarcoma since the localization of 
the long C-terminal domain of MTDH would provide clues to better understand its functions 
and the underlying mechanisms.  
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Results 
MTDH expression profile in various osteosarcoma cell lines 
After MTDH overexpression was confirmed in osteosarcoma samples in chapter 3, we 
wanted to explore the expression of MTDH in established osteosarcoma cell lines. We began 
by assessing MTDH expression at the protein level. According to western blotting analysis, 
MTDH protein was overexpressed in all 6 osteosarcoma cell lines in comparison with the 
normal control hFOB cells: 16 fold increase in CCHD, 10 fold increase in LM7, 10 fold 
increase in SAOS2, 15 fold increase in SJSA, 9 fold increase in HOS, and 11 fold increase 
MG63 (Figure 11). In the meantime, real-time PCR analyses demonstrated that osteosarcoma 
cell lines had upregulated MTDH at the level of transcription as well (Figure 12). Compared 
to the normal control cell line hFOB, the mRNA expression of MTDH was increased by 10.6 
fold, 1.8 fold, 2.5 fold, 3.5 fold, 2.1 fold, and 2.3 fold in CCHD, LM7, SAo2, SJSA, HOS, 
and MG63 cell lines respectively. 
Figure 11 
 
Figure 11. MTDH expression is upregulated in osteosarcoma cells.  The protein 
expression of MTDH in normal human fetal osteoblastic cells (hFOB) and a panel of human 
osteosarcoma cell lines was analyzed by Western blot. Beta-actin was used as a loading 
control. 
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Figure 12 
                       
Figure 12. MTDH is upregulated in osteosarcoma cells at the mRNA level. Relative 
mRNA expression of MTDH in hFOB and indicated osteosarcoma cell lines was determined 
by real-time PCR. Expression data were normalized with GAPDH. Fold change of gene 
expression in each osteosarcoma cell line was relative to hFOB. *P≤0.05, **P≤0.01, 
***P≤0.001 vs. hFOB cells. Bar graphs represent mean ± SEM. 
 
 
Localization of MTDH in osteosarcoma cells 
To determine the localization of MTDH in osteosarcoma cells, HOS and CCHD cells 
were examined by immunofluorescence (IF) microscopy using anti-MTDH antibody and 
Alexa 488-labeled secondary antibody (Figure 13).  IF analysis of fixed and permeabilized 
HOS and CCHD cells demonstrated diffuse cytoplasmic staining of MTDH. Concentrated 
immunoreactivity for MTDH was also detected at the cell edges in both CCHD and HOS 
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cells. No significant nuclear distribution could be found. These observations implied that 
MTDH protein is primarily localized to the cytoplasm and cell membrane in osteosarcoma 
cells. 
 
Figure 13 
 
 
Figure 13. Expression and localization of MTDH in osteosarcoma cells. Acetone-fixed 
HOS and CCHD cells were stained with rabbit-anti-MTDH primary antibody followed by 
Alexa 488-labeled anti-rabbit secondary antibody. Cell nuclei were counterstained with 
Hoechst. Green fluorescence represents the immunoreactivity for MTDH. Blue fluorescence 
represents staining of nuclei. All images were taken on a Nikon fluorescence microscope 
under 100X magnification. 
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Cell surface expression and membrane topology of MTDH in osteosarcoma cells 
To confirm the cell surface localization of MTDH, we used flow cytometry to evaluate 
the expression and topology of MTDH protein on the cell membrane. Antibodies specific for 
amino acid residues 315-461 of MTDH protein were allowed to bind only to the outside of 
non-permeabilized osteosarcoma cells, ensuring that any signal detected was from the outer 
cell membrane. While normal hFOB cells had virtually no detectable cell surface MTDH 
expression, all osteosarcoma cell lines assessed expressed abundant level of cell surface 
MTDH protein (Figure 14). The results indicated that, in osteosarcoma at least, MTDH is 
localized at the cell surface as a type II transmembrane protein with a short cytoplasmic N-
terminal domain and a long extracellular C-terminal domain which could be involved in 
potential interactions with extracellular components.  
The type II topology of MTDH in osteosarcoma cells was further confirmed by western 
blot analyzing phosphorylation of serine residues located on the C-terminal segment (Figure 
15). While there were multiple proteomic studies that identify serine-phosphorylated peptide 
fragments apparently derived from MTDH, we could not detect any phosphoserine signal in 
our immunoprecipitated MTDH samples. This observation, contrary to previous findings 
from multiple phosphorylation studies, suggested that the C-terminal domain of MTDH 
which is rich in phosphorylation sites localizes to the extracellular space, indicating a type II 
topology of MTDH protein in osteosarcoma cells. 
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Figure 14 
 
 
Figure 14. Cell surface expression and membrane topology of MTDH in osteosarcoma 
cells. Cell surface expression of MTDH was assessed in non-permeabilized hFOB and six 
osteosarcoma cell lines by flow cytometry using rabbit-anti-MTDH (315-461 a.a.) antibody 
in combination with a secondary PE-conjugated antibody. Representative histograms are 
shown. 
 
 
 
 
 
 
 49 
 
Figure 15. 
                           
 
Figure 15. Analysis of phosphorylation status of MTDH in osteosarcoma cells. Whole-
cell lysates of HOS cells were subjected to co-immunoprecipitation with anti-MTDH 
antibody or normal IgG. The precipitated proteins (lane 1 and lane 2) and the whole cell 
lysates (lane 3 and lane 4) were transferred to nitrocellulose membrane and probed with anti-
phosphoserine and anti-MTDH antibodies.  
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Summary 
 
In this chapter we explored the expression, localization, and topology of MTDH in 
established osteosarcoma cell lines through multiple experimental approaches. We have 
demonstrated through western blotting and real-time quantitative PCR that compared to 
normal human osteoblasts, osteosarcoma cell lines ubiquitously expressed high level of 
MTDH at both protein and mRNA levels. Immunofluorescence analysis of the distribution of 
MTDH protein in HOS and CCHD cells displayed uniform cytoplasmic and cell membrane 
localization. By performing flow cytometry analysis on non-permeabilized osteosarcoma and 
control cells with an anti-MTDH antibody that targets the C-terminal domain of MTDH, we 
confirmed the overexpression of MTDH on cell surface and demonstrated that MTDH is a 
type II transmembrane protein in osteosarcoma cells. This topology was supported by further 
evidence obtained from the analysis of MTDH phosphorylation status in HOS cells. 
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Chapter 5. Inhibition of MTDH suppresses invasive properties of osteosarcoma cells  
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Rationale: 
Previous studies of clinical samples have established a positive correlation between 
high MTDH expression level and poor patient prognosis (68, 70, 78, 80-83). The data 
collected in Chapter 3 revealed a significant increase in MTDH expression in metastatic 
lesions compared to primary tumors. In the meantime, high expression of MTDH has been 
associated with increased risk of metastasis in osteosarcoma. Given the results presented in 
Chapter 4 that MTDH is overexpressed in osteosarcoma cell lines as compared with normal 
human osteoblasts, we hypothesized that MTDH expression promotes metastasis-associated 
behaviors in osteosarcoma cells.  
In this chapter, we wanted to investigate the function(s) of MTDH, particularly those 
expressed on the cell surface, in osteosarcoma metastasis by assessing the impact of MTDH 
inhibition on osteosarcoma cell proliferation, migration, and invasion in vitro. We planned to 
use two different approaches to inhibit MTDH: silencing endogenous MTDH gene 
expression by retrovirus-mediated shRNA, and blocking surface-bound MTDH with anti-
MTDH antibody. For the experiments performed in this chapter, we have chosen HOS and 
CCHD cell lines, both of which have abundant expression of MTDH and are highly invasive 
according to literature and previous studies conducted in our lab. We anticipated that MTDH 
inhibition leads to decreased cell invasion and migration ability.  
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Results 
Knockdown of endogenous MTDH reduces proliferation in osteosarcoma cells 
To examine the effects of MTDH downregulation on osteosarcoma cells, we used 
retrovirus-mediated shRNA targeting MTDH to stably knock down MTDH expression in 
osteosarcoma cell lines HOS and CCHD. After a week of selection by puromycin, the 
knockdown efficiency of MTDH in each cell line was validated by western blotting analysis. 
A significant reduction in MTDH protein level (80% and 90% in SH-4 and SH-6 respectively) 
was observed in cells transduced with MTDH-specific shRNA constructs when compared 
with the control cells transduced with a scrambled sequence (Figure 16).   
 
Figure 16. 
 
Figure 16. Retrovirus-mediated shRNA targeting MTDH effectively reduces MTDH 
expression in HOS and CCHD cells.  MTDH knockdown in HOS and CCHD was 
confirmed by western blotting analysis of whole cell lysates extracted from control and 
MTDH-knockdown osteosarcoma cells. (SC: scramble control; SH-4: MTDH-specific 
shRNA construct #4; SH-6: MTDH-specific shRNA construct #6). Beta-actin was used as a 
loading control. Densitometric analysis (Image J Processing Software, NIH) was applied to 
calculate the knockdown efficiency. 
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Next, we used an automated Coulter counter (Vi-Cell) to evaluate the effect of MTDH 
silencing on the proliferation rate of HOS and CCHD cells for a period of 6 days (Figure 17). 
MTDH depletion caused a modest reduction in cell yield of HOS cells on day 6 (p<0.01). We 
also observed a significant decrease in proliferation of MTDH-knockdown CCHD cells 
compared with control cells on day 4 and day 6 (p<0.001).  
 
Figure 17 
 
Figure 17. Downregulation of MTDH reduces cell proliferation in osteosarcoma cells. 
Cell proliferation was determined by automated cell counting after 0, 2, 4, and 6 days of 
incubation of control cells (NC) and MTDH-knockdown cells (shMTDH-4 and shMTDH-6). 
Results are shown as mean ± SEM of three replicates and they are representative of three 
independent experiments.  
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Downregulation of MTDH has marginal effect on clonogenic ability of osteosarcoma 
cells 
To determine whether MTDH knockdown alters clonal growth of osteosarcoma cells, 
we performed colony formation assay on control and MTDH-knockdown HOS and CCHD 
cells. When compared to the control HOS cells (137.3±4.3 colonies), a minor decrease in 
the number of colony formed was observed in HOS-SH-4 cells (114.0±7.1 colonies, p<0.05) 
while no significant reduction was found in HOS-SH-6 cells (130.3±7.9 colonies, ns). 
Similar results were shown in CCHD cells. CCHD-SH-4 cells (288.7±9.6 colonies, p<0.05) 
and CCHD-SH-6 cells (240.0±5.3 colonies, p<0.001) formed slightly fewer colonies than 
the control CCHD-NC cells (332.7±6.6 colonies). These results indicated that MTDH 
expression has very limited effect on clonogenic ability of osteosarcoma cells. 
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Figure 18. 
 
Figure 18. MTDH knockdown slightly decreases the colony formation ability of 
osteosarcoma cells. Control and MTDH-knockdown HOS and CCHD cells were seeded in 
6-well plates at very low density in triplicates and cultured under standard conditions. After 2 
weeks of incubation, cells were fixed and stained with 0.05% crystal violet PBS solution. 
Colonies with 50 or more cells were counted. Results are shown as mean ± SEM of three 
replicates. *P≤0.05, **P≤0.01, ***P≤0.001 vs. control cells. 
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MTDH knockdown inhibits osteosarcoma cell migration and invasion 
To explore the functional role of MTDH in osteosarcoma metastasis, we used transwell 
migration assay and matrigel invasion assay to examine the effects of MTDH knockdown on 
cell aggressiveness. It has been shown that downregulation of MTDH by shRNA triggered a 
significant reduction in the number of migrated cells of HOS and CCHD after 24 hours when 
compared to control cells (HOS: 429.3±7.0 cells/field in SH-4 and 310.0±80.5 cells/field in 
SH-6 vs. 1201.0±98.4 cells/field in NC; CCHD: 128.7±39.7 cells/field in SH-4 and 107.7
±22.1 cells/field in SH-6 vs. 402.3±73.7 cells/field in NC) (Figure 19). We have also 
demonstrated in both HOS and CCHD cells that efficient knockdown of MTDH, compared to 
scrambled control shRNA, resulted in profound reduction in invasive ability of osteosarcoma 
cells in vitro (HOS: 135.0±32.8 cells/field in SH-4 and 163.7±10.4 cells/field in SH-6 vs. 
565.0±43.7 cells/field in NC; CCHD: 18.7±0.7 cells/field in SH-4 and 16.7±4.1 cells/field 
in SH-6 vs. 216.0±31.9 cells/field in NC) (Figure 20). Taken together, these data strongly 
suggested that MTDH promotes osteosarcoma aggressiveness by mediating cell invasion and 
migration. 
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Figure 19 
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Figure 19. Silencing endogenous MTDH inhibits migration of HOS and CCHD cells.   In 
vitro cell migration was performed in the 24-well Corning Transwell polycarbonate 
membrane cell culture inserts with 8-μm pore size (Corning). After incubation for 24 hours, 
the migrated cells were fixed, stained with Hema-3, and counted under a microscope. 
Representative pictures (right) and quantification of migrated cells (left) from transwell 
migration assays are displayed. Results are shown as mean ± SEM (cells/field) of three 
replicates and are representative of three independent experiments. *P≤0.05, **P≤0.01, 
***P≤0.001 vs. control cells. 
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Figure 20 
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Figure 20. Downregulation of MTDH leads to decreased invasive ability of 
osteosarcoma cells. The invasive ability of osteosarcoma cells was evaluated by using 24-
well BD BioCoat Matrigel invasion chambers with 8-μm pore size. After 48h incubation, the 
penetrated cells were fixed, stained with Hema-3, and counted under a microscope 
Representative pictures (right) and quantification of penetrated cells (left) from matrigel 
invasion assays are shown. Results are shown as mean ± SEM (cells/field) of three replicates 
and are representative of three independent experiments. *P≤0.05, **P≤0.01, ***P≤0.001 vs. 
control cells. 
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Blockade of cell surface MTDH with antibody inhibits migration and invasion 
Since we have defined the cell-surface localization for MTDH in chapter 4, we wished 
to know if steric interference with MTDH’s extracellular functions might cast a similar effect. 
Transwell migration and matrigel invasion assays were performed on HOS and CCHD cells 
in the presence of an anti-MTDH antibody specific for an epitope within the extracellular C-
terminal domain compared to an isotype control antibody. A significant reduction in 
migration was demonstrated in both HOS and CCHD cells incubated with the MTDH-
blocking antibody when compared with cells treated with the control IgG (HOS: 197.0±20.0 
cells/field in anti-MTDH group vs. 994.0±92.0 cells/field in normal IgG group; CCHD: 
304.0±7.0 cells/field in anti-MTDH group vs. 688.0±33.9 cells/field in normal IgG group) 
(Figure 21). Results from the invasion assay revealed that blocking cell surface MTDH with 
anti-MTDH antibody effectively decreased in vitro invasiveness of HOS and CCHD cells 
(HOS: 95.3±25.2 cells/field in anti-MTDH group vs. 299.0±49.2 cells/field in normal IgG 
group; CCHD: 138.7±17.3 cells/field in anti-MTDH group vs. 345.0±51.0 cells/field in 
normal IgG group) (Figure 22). 
To determine whether the effects on cell migration and invasion from anti-MTDH 
antibodies resulted from antibody-induced cellular cytotoxicity, cell viability was evaluated 
under the exact same conditions. Anti-MTDH antibody did not affect cell viability at the 
indicated concentration within the same period of time (Figure 23). Taken together, these 
results suggested that MTDH located on the cell surface is essential for mediating cell 
motility and invasiveness in osteosarcoma. 
 
 
 63 
 
Figure 21 
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Figure 21. Inhibition of cell surface MTDH leads to significantly decreases motility of 
osteosarcoma cells. HOS and CCHD cells were co-incubated with rabbit IgG or rabbit-anti-
MTDH antibody at a final concentration of 7.5 µg/ml. After 24-hour of incubation in the 
transwell Boyden chamber, the migrated cells were fixed, stained with Hema-3, and counted 
under a microscope. Representative pictures (right) and quantification of migrated cells (left) 
from migration assay are displayed. Results are shown as mean ± SEM (cells/field) of three 
replicates and are representative of three independent experiments. *P≤0.05, **P≤0.01, 
***P≤0.001 vs. control cells. 
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Figure 22 
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Figure 22. Anti-MTDH antibody inhibits osteosarcoma cell invasiveness. HOS and 
CCHD cells were co-incubated with rabbit IgG or rabbit-anti-MTDH antibody at a final 
concentration of 7.5 µg/ml. After 48-hour of incubation in the invasion chamber, the 
penetrated cells were fixed, stained with Hema-3, and counted under a microscope. 
Representative pictures (right) and quantification of penetrated cells (left) from invasion 
assay are displayed. Results are shown as mean ± SEM (cells/field) of three replicates and 
are representative of three independent experiments. *P≤0.05, **P≤0.01, ***P≤0.001 vs. 
control cells. 
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Figure 23 
 
Figure 23. Anti-MTDH antibody has no significant impact on osteosarcoma cell 
proliferation at indicated concentration. HOS and CCHD cells were co-incubated with 
rabbit IgG or rabbit-anti-MTDH antibody at a final concentration of 7.5 µg/ml. After 48-hour 
of incubation under standard culture conditions in a 6-well plate, cell yield was determined 
by automated cell counting using Vi-Cell. Results are shown as mean ± SEM of three 
replicates and are representative of three independent experiments.  
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Summary 
In this chapter we investigated the biological significance of MTDH in the aggressive 
behavior of osteosarcoma. The impacts of MTDH knockdown on osteosarcoma cell 
proliferation, colony formation, migratory and invasive abilities were tested by shRNA-
mediated gene silencing in HOS and CCHD cells. In the MTDH knockdown studies, we have 
shown that downregulation of MTDH had limited effect on the proliferative and clonogenic 
ability of osteosarcoma cells. However, we observed a more significant reduction in 
transwell migration and matrigel invasion of MTDH-knockdown cells compared with the 
control cells. To further understand the function(s) of MTDH located on the cell surface, we 
used an anti-MTDH antibody which targets the extracellular C-terminal domain to interfere 
with MTDH’s extracellular functions and assessed its impacts on osteosarcoma cell 
migration and invasion. We have shown that blocking MTDH expressed on the cell 
membrane significantly decreased osteosarcoma cell motility and effectively inhibited cell 
invasion through matrigel. Altogether, these results indicate that MTDH plays a pivotal role 
in mediating pro-metastatic activities in osteosarcoma cell models. 
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Chapter 6. Knockdown of MTDH inhibits pulmonary metastasis in vivo 
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Rationale: 
Given the results presented in Chapter 5 that MTDH knockdown decreases the invasive 
properties of osteosarcoma cells in vitro, we thus decided to evaluate the role of MTDH in 
osteosarcoma metastasis in an animal model. Since high MTDH expression promotes 
osteosarcoma cell migration and invasion, and is associated with increased risk of metastasis 
in clinical datasets, we anticipated that MTDH knockdown would decrease the metastatic 
potential of osteosarcoma cells and therefore inhibit pulmonary metastasis in vivo.  
To better mimic the whole processes of tumor progression and metastasis, we 
developed a novel bioluminescent orthotopic osteosarcoma xenograft murine model with 
CCHD cells. The stable MTDH-knockdown and scrambled control CCHD cells were labeled 
with luciferase and injected into the tibia of 6-week-old NOD/SCID/IL2Rγ-deficient mice. 
Primary tumors were allowed to develop, followed by spontaneous pulmonary metastases. 
Both the primary tumor and the lung metastases were monitored weekly by IVIS spectrum 
imaging system and the luciferase signals were quantified. After the 6-week incubation 
period, all mice were sacrificed and lungs were resected for further analysis. 
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Results 
MTDH knockdown impedes primary tumor growth and inhibits pulmonary metastasis 
While in vitro analyses are helpful in determining a protein’s role in specific behaviors 
like proliferation, migration and invasion, assessment of metastasis requires in vivo analysis. 
To determine whether MTDH expression is essential for metastasis, we utilized luciferase-
labeled CCHOD cells, transduced with either the same MTDH-specific shRNA used in 
Chapter 5 or scrambled control shRNA. To ensure that our results were not compromised by 
contamination with untransduced cells, which might have an advantage in both proliferation 
and metastatic potential, clonal populations were derived from both the MTDH-knockdown 
and scrambled control cells. One clonal line from each group was used for all in vivo studies.   
One million tumor cells were injected into the tibia of each NOD/SCID/IL2Rγ-/- 
xenograft host mouse (n=7 of MTDH-knockdown and control groups) and tumor growth was 
measured weekly by bioluminescence imaging. Quantification of the bioluminescent signals 
indicated that MTDH knockdown impeded primary tumor growth (Figure 24B) and inhibited 
development of spontaneous lung metastases (Figure 24C). All mice in the control group 
developed massive lung metastases 6 weeks after cancer cell inoculation, and some mice 
demonstrated multiple metastatic sites including bones, livers, and kidneys (Figure 24A). By 
contrast, mice in the MTDH-knockdown group had smaller primary tumors and significantly 
fewer lung metastases. Three mice showed no evidence of metastatic disease and the other 
four mice developed 5 or fewer metastatic lesions. Both primary and metastatic tumor burden 
of the control group was remarkably higher than that of the MTDH-knockdown group.  
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Figure 24 
 
Figure 24. Knockdown of MTDH reduces primary tumor growth and inhibits 
pulmonary metastasis. A) Displayed are images of representative mice at the fourth week 
after injection. Primary tumor and lung metastasis burden of NOD/SCID/IL2Rγ-deficient 
mice inoculated orthotopically with luciferase-labeled CCHD cells with or without MTDH 
knockdown were monitored weekly by bioluminescent imaging. Quantification of the 
bioluminescent signals emitted from primary tumor (A) and lung metastases (B) are shown. 
Each data point represents mean ± SEM of 7 mice. 
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Tumor-bearing mice from both groups were sacrificed at 6 weeks after inoculation and 
the mouse lungs were harvested, photographed, and weighed. Microscopic examination of 
the H&E stained lung sections revealed that downregulation of MTDH significantly 
decreased the number of metastatic nodules developed in lung (Figure 25).  
 
Figure 25 
 
Figure 25. Downregulation of MTDH inhibits lung metastasis in vivo. Image of whole 
lungs isolated from mice sacrificed at six weeks after tumor cell inoculation (top). 
Representative H&E stained lung sections of mice at the sixth week after intratibial injection 
of one million CCHD-NC or CCHD-shMTDH cells (bottom).  
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Further analysis of the resected mouse lungs revealed that the mean lung weight 
(p<0.05, Figure 26A) and the mean number of metastatic nodules (p<0.0001, Figure 26B) 
were remarkably reduced in the MTDH-knockdown group. The mean lung weight of mice 
inoculated with MTDH-knockdown cells was 23% less than that of the control group. In the 
meantime, an average of 11.29±1.52 metastatic tumor nodules were detected per field in 
lungs isolated from the control group, while mice in the MTDH-knockdown group developed 
an average of 0.51±0.26 metastatic nodules per field.  
 
Figure 26 
 
Figure 26. MTDH knockdown decreases lung tumor burden and reduces the number of 
metastatic nodules. A) Whole lungs isolated from mice sacrificed at the sixth week post 
injection were weighed. Data are displayed as a scatter dot blot. B) Quantified lung 
metastases are depicted as the number of metastatic nodules per field in a scatter dot blot. 
Lines and whiskers represent mean ± SEM of 7 mice.  
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To be certain that the reduction in metastasis was not solely due to the reduced 
proliferation of primary tumors, a parallel group of mice (n=3) inoculated with MTDH-
knockdown cells were allowed to live to 12 weeks after initial inoculation, during which time 
the primary tumors reached a size comparable to that of the control group near the 
termination of the experiment while no sign of lung metastasis was detected through 
bioluminescent imaging (Figure 27). When their lungs were analyzed, no metastatic nodule 
was identified. Hence, the low rate of metastasis observed in the MTDH-knockdown group 
was due to the substantially reduced metastatic capacity of these cells. 
Figure 27 
 
Figure 27. Inhibition of metastasis observed in MTDH-knockdown group is due to 
decreased metastatic ability of osteosarcoma cells. Quantification of the bioluminescent 
signals emitted from primary tumor (A) and lung metastases (B) are shown here. Each data 
point represents mean ± SEM of 7 mice in control group and 3 mice in CCHD-shMTDH 
group. 
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Metastasized osteosarcoma cells have upregulated MTDH expression 
Immunohistochemical analysis of primary and metastatic tumors harvested from mice 
of control and MTDH-knockdown groups demonstrated that MTDH expression was 
dramatically enhanced in pulmonary metastatic nodules in comparison to that in primary 
tumors (Figure 28). When we examined the tissue samples from the four mice that developed 
lung metastasis in MTDH-knockdown group, we found that the rare metastatic nodules 
demonstrated re-expression of MTDH, while MTDH expression was still suppressed in 
primary tumors.  
Figure 28 
   
Figure 28. Metastasized osteosarcoma cells display upregulated MTDH expression. 
Representative examples of MTDH-immunostaining intensity in primary tumors and lung 
metastases are shown here. Images of higher magnification are displayed in the bottom left 
corner. 
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Summary 
Based on conclusion from Chapter 5 that MTDH promotes osteosarcoma cell migration 
and invasiveness in vitro, we hypothesized that knockdown of MTDH would inhibit 
pulmonary metastasis of osteosarcoma in vivo. To test this hypothesis, we used non-invasive 
bioluminescence imaging to investigate the role of MTDH in tumor progression and 
metastasis in an orthotopic osteosarcoma xenograft mouse model.  
By comparing the intensity of bioluminescent signal emitted from tibia and lung 
between control mice and the mice inoculated with stable MTDH-knockdown cells, we 
demonstrated that downregulation of MTDH in osteosarcoma cells delayed primary tumor 
growth and inhibited pulmonary metastasis in vivo. Further analysis of the resected lungs 
revealed that MTDH knockdown decreased metastatic tumor burden and significantly 
reduced the number of metastatic nodules developed in lung.   
Additionally, immunohistochemical analysis of primary tumor and lung sections from 
experimental animals revealed that osteosarcoma cells that have successfully metastasized to 
the lung demonstrated upregulated MTDH level. This observation is consistent with the 
patient data (Figure 8) obtained from osteosarcoma tissue microarray analysis presented in 
Chapter 3. It is worth mentioning that rare pulmonary metastases of mice bearing MTDH-
knockdown tumors had re-expressed MTDH despite arising from a clonal population 
expressing shRNA specific for MTDH. Although the mechanism by which aggressive 
osteosarcoma cells overcome shRNA-mediated gene silencing is unknown, this finding 
suggested a pivotal role of MTDH in promoting osteosarcoma metastasis. 
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Chapter 7. MTDH modulates cell adhesion to ECM through interaction with Laminin 
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Rationale 
Through functional, in vivo analyses, we have clearly demonstrated in previous 
chapters that knocking down endogenous MTDH by shRNA inhibits osteosarcoma invasion 
and metastasis. More importantly, MTDH expressed on the cell membrane has been found to 
play an essential role in mediating osteosarcoma cell invasiveness as our results showed that 
steric interference of the extracellular domain of MTDH by anti-MTDH antibody 
significantly decreased cell motility and inhibited cell invasion through matrigel. Since 
invading through the extracellular matrix is a prerequisite for tumor cell metastasis, these 
observations led us to reason that surface-bound MTDH mediates interaction and signal 
transduction between tumor cells and non-cellular protein components of the extracellular 
matrix (ECM), which facilitates cell motility and invasive properties.  
To search for extracellular binding partners for MTDH, a series of adhesion assays 
were performed to evaluate the adhesion ability of osteosarcoma cells with or without 
MTDH inhibition to major components of ECM, including Fibronectin, Collagen, and 
Laminin. After we identified the candidate MTDH-interacting protein, we performed bi-
directional co-immunoprecipitation to confirm the interaction. Whole cell lysates of HOS 
cells cultured in standard conditions or briefly treated with diluted matrigel were subjected to 
anti-MTDH immunoprecipitation, followed by SDS-PAGE separation and western blotting. 
By identifying this novel connection between MTDH and ECM, we wished to establish a 
new paradigm for the function of MTDH in mediating tumor cell metastasis. 
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Results 
MTDH mediates osteosarcoma cell adhesion to ECM protein Laminin 
To determine whether MTDH is involved in modulation of cell adhesion to ECM, we 
performed a set of adhesion assays on 96-well plates pre-coated with matrigel and different 
ECM proteins, comparing control and MTDH-knockdown cells (Figure 29). HOS and CCHD 
cells with downregulated MTDH displayed a significantly decreased adhesion to matrigel 
and Laminin compared with their control counterparts. However, there were no statistically 
significant differences in adhesion to Fibronectin and Collagen IV in both HOS and CCHD 
cell lines. 
Since we showed that cell-surface MTDH plays a pivotal role in promoting cell 
invasion, we next investigated whether blocking the cell surface-bound MTDH with antibody 
affected the ability of osteosarcoma cells to adhere to the ECM proteins (Figure 30). MTDH-
specific antibody decreased adhesion of HOS cells to matrigel, Laminin, and Fibronectin by 
approximately 70%, 80%, and 20% respectively as compared with that observed in the 
control cells treated with normal IgG (Figure 30A). Similar results were seen with CCHD 
cells, with 70%, 90% and 50% reduction in cell attachment to matrigel, Laminin, and 
Fibronectin in the presence of MTDH-blocking antibody (Figure 30B). Meanwhile, adhesion 
of the two cell lines to Collagen IV was not significantly altered by anti-MTDH antibody. 
These results suggested that the surface-bound MTDH plays a key role in mediating adhesion 
of cancer cells to the ECM.  This effect seemed likely to be achieved through interaction with 
Laminin, which is a major component of the basement membrane (100).  
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Figure 29 
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Figure 29. Downregulation of MTDH decreases osteosarcoma cell adhesion to matrigel 
and Laminin. HOS (A) and CCHD (B) cells were harvested, suspended in serum-free 
DMEM medium, and seeded in triplicate onto 96-well plates pre-coated with Matrigel, 
Fibronectin, Laminin, or Collagen IV. After 1-2h incubation, unattached cells were removed 
by rinsing three times with PBS while the input control groups were left unwashed. 
Histograms represent the percentage of cells remaining bound to each substrate compared to 
unwashed controls. Data represent mean ± SEM of three replicates from independent 
experiments. *P≤0.05, **P≤0.01, ***P≤0.001 vs. control cells. 
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Figure 30. 
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Figure 30. Blocking cell surface MTDH inhibits osteosarcoma cell adhesion to matrigel 
and Laminin. HOS (A) and CCHD (B) cells were treated with rabbit anti-MTDH antibody 
or normal rabbit IgG at a final concentration of 7.5µg/ml. After 1-2h incubation in 96-well 
plates pre-coated with Matrigel, Fibronectin, Laminin, or Collagen IV, unattached cells were 
removed by rinsing three times with PBS while the input control groups were left unwashed. 
Histograms represent the percentage of cells remaining bound to each substrate compared to 
unwashed controls. Data represent mean ± SEM of three replicates from independent 
experiments. *P≤0.05, **P≤0.01, ***P≤0.001 vs. control cells. 
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Identification of Laminin as an MTDH-interacting protein 
To validate the interaction between MTDH and extracellular Laminin, we performed 
bi-directional co-immunoprecipitation (co-IP) experiments with antibodies targeting these 
two proteins. Whole cell lysates extracted from HOS cells cultured under standard conditions 
or exposed briefly to diluted matrigel were subjected to immunoprecipitation with anti-
MTDH antibody. Western blot analysis with anti-Laminin antibodies demonstrated that 
Laminin could only be detected in the cells pre-treated with diluted matrigel (Figure 31). 
Reciprocal co-IP was performed with anti-Laminin antibody. Western blotting of the 
immunoprecipitated protein complex with anti-MTDH antibody indicated that MTDH was 
pulled down along with Laminin from the cells co-incubated with diluted matrigel (Figure 
32). These results suggest that MTDH and Laminin sustain a strong protein-protein 
interaction in osteosarcoma cell model. 
 To determine the specificity of the interaction between MTDH and Laminin, we 
investigated the potential connection between MTDH and Fibronectin which is another major 
protein component of ECM. Whole cell lysates from control cells or cells co-incubated with 
diluted matrigel were subjected to anti-MTDH co-IP and probed with anti-Fibronectin 
antibody in western blot. We could not detect Fibronectin being co-immunoprecipitated with 
MTDH in this experiment (Figure 33). These data indicate that MTDH located on the cell 
surface regulates cell-matrix adhesion by interacting with extracellular Laminin, thus having 
a key role in promoting invasiveness and metastasis. 
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Figure 31 
    
 
Figure 31. Identification of Laminin as MTDH-interacting partner. Lysates from HOS 
cells without exposure to matrigel (lane 1 and lane 2) or HOS cells briefly exposed to 
extracellular matrix proteins contained in matrigel (lane 3 and lane 4) were 
immunoprecipitated with anti-MTDH antibody or normal rabbit IgG, and immunoblotted 
with anti-Laminin antibody. Input control displayed at the bottom represents the protein level 
of MTDH and Laminin in each sample before co-IP. IP: immunoprecipitation; WB: western 
blot. 
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Figure 32 
      
 
Figure 32. MTDH is pulled down with Laminin in the same protein complex in a co-IP 
experiment. Lysates from HOS cells without exposure to matrigel (lane 1 and lane 2) or 
HOS cells briefly exposed to extracellular matrix proteins contained in matrigel (lane 3 and 
lane 4) were immunoprecipitated with anti-Laminin antibody or normal rabbit IgG, and 
immunoblotted with anti-MTDH antibody. Input control displayed at the bottom represents 
the protein level of MTDH and Laminin in each sample before co-IP. IP: 
immunoprecipitation; WB: western blot. 
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Figure 33 
 
   
 
Figure 33. MTDH has no evident interaction with Fibronectin in ECM. Lysates from 
HOS cells without exposure to matrigel (lane 1 and lane 2) or HOS cells briefly exposed to 
extracellular matrix proteins contained in matrigel (lane 3 and lane 4) were 
immunoprecipitated with anti-MTDH antibody or normal rabbit IgG, and immunoblotted 
with anti-Fibronectin antibody. Input control displayed at the bottom represents the protein 
level of MTDH and Fibronectin in each sample before co-IP. IP: immunoprecipitation; WB: 
western blot. 
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Summary 
In this chapter we hypothesized that MTDH expressed on the cell surface modulates 
cell-ECM interactions by binding to non-cellular ECM proteins. We propose that the protein-
protein interaction between surface-bound MTDH and extracellular ECM proteins promotes 
tumor cell adhesion to ECM, therefore facilitating cell migration and invasion through ECM 
and basement membrane barriers. To test this hypothesis and identify the candidate 
interacting-partner of MTDH, we evaluated cell adhesive ability to matrigel and various 
ECM protein components in HOS and CCHD cells with constitutive MTDH knockdown or 
blockade of MTDH at the cell surface, followed by a bi-directional co-IP.  
 Through a series of cell adhesions assays, we observed significantly decreased cell 
adhesion to matrigel and Laminin in MTDH-knockdown osteosarcoma cell lines as 
compared to control osteosarcoma cells after 1-2 hours of incubation time. Interestingly, 
MTDH-knockdown cells showed very little difference in cellular adhesive ability to 
Fibronectin and Collagen IV when compared to the control cells. Similarly, we saw a 
remarkable reduction in cellular adhesion to marigel and Laminin for HOS and CCHD cells 
treated with antibodies targeting the extracellular domain of MTDH in relation to the control 
cells co-incubated with equal concentrations of normal IgG. A modest decrease in adhesion 
to Fibronectin was observed in the antibody-blocking experiments while no difference was 
detected in cell adhesion to Collagen IV. These results suggest that Laminin could be the 
candidate protein involved in the interaction between cell surface MTDH and the ECM. Bi-
directional co-IP with anti-MTDH antibody and anti-Laminin antibody confirmed that these 
two proteins exist in the same protein complex and sustain a strong protein-protein 
interaction. The fact that Fibronectin, another major component of ECM, could not be co-
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immunoprecipiated with MTDH supported the specificity of the interaction between MTDH 
and Laminin. By establishing this novel connection between MTDH and extracellular 
Laminin, our research not only confirms the importance of the cell surface localization of 
MTDH in osteosarcoma, but also provides a mechanism that is involved in the metastasis-
promoting actions of MTDH. 
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Chapter 8. Discussion: Implications of Results and Future Directions 
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Implications of Results 
Accumulating evidence suggests that the aberrant MTDH expression observed in many 
malignant tumors is often correlated with poor clinical outcomes (68, 70, 78, 80-83). The 
critical role of MTDH in tumor cell proliferation, chemoresistance, angiogenesis, invasion 
and metastasis has been verified by a number of functional studies performed in various 
cancer models (63, 69, 70, 73, 74, 77, 78, 84, 85, 90). However, most of the recent studies 
about MTDH focus exclusively on common adult cancers such as breast cancer and liver 
cancer. There was no report on expression status of MTDH in osteosarcoma when we started 
this project. Since the most common cause of mortality associated with osteosarcoma is 
pulmonary metastasis, identification and characterization of new molecular targets for the 
development of anti-metastasis therapeutic strategies will be valuable for treating this disease. 
Moreover, the mechanism of how MTDH mediates tumor cell aggressiveness and metastasis 
remained largely unknown. To extend our understanding of the biological functions of 
MTDH and to identify novel therapeutic targets for osteosarcoma, we established three 
objectives for our research: 1) investigating the expression pattern of MTDH in osteosarcoma 
patient samples and its relationship to metastatic risk and patients’ outcome in clinic; 2) 
identifying the function(s) of MTDH in tumor progression and metastasis of osteosarcoma; 3) 
elucidating the mechanism(s) by which MTDH mediates tumor aggressiveness. To achieve 
these three goals, we conducted a series of studies using clinical datasets and specimens, 
osteosarcoma cell models, and an orthotopic osteosarcoma xenograft mouse model. In the 
present study we have shown that MTDH, a cell surface protein correlated with worse 
outcome in osteosarcoma and many other cancers, plays a decisive role in multiple steps of 
tumor metastasis. 
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MTDH is widely expressed in osteosarcoma and correlates with metastasis 
We have demonstrated that MTDH is highly expressed in both osteosarcoma cell lines 
and patient tumor specimens. Western blot and Q-PCR analyses of a panel of six 
osteosarcoma cell lines and the normal control cell line derived from human fetal osteoblasts 
revealed that osteosarcoma cells had upregulated MTDH expression both at the protein and 
mRNA levels (Figure 11 and 12 ). Evaluation of MTDH expression in a tissue microarray 
containing 73 osteosarcoma samples showed that MTDH could be detected in 63% of 
primary osteosarcoma tumors and 88% of metastatic tumors specimens (Figure 7 and Table 
1). More importantly, after examining IHC staining intensities of MTDH in 9 matched pairs 
of primary and metastatic osteosarcoma specimens, we found that MTDH expression was 
remarkably increased from primary to metastatic tumors in the same patient (Figure 8 and 
Table 2). Similarly, we observed in three other clinical datasets of melanoma and prostate 
cancer that metastatic tumor lesions had significantly higher level of MTDH expression than 
primary tumor specimens (Figure 4) 
 In support of this notion, analyses of survival data and related clinical outcomes in 
melanoma and breast cancer datasets revealed that patients with high MTDH expression 
developed metastatic disease earlier and had a shorter overall survival than the low-MTDH 
group (Figure 5 and 6). Comparative analysis of metastasis-free survival in a cohort of high-
grade osteosarcoma patients has also demonstrated that MTDH overexpression correlated 
with a higher risk of metastatic relapse and is associated with worse clinical outcome (Figure 
9 and 10). These results strongly indicated that MTDH may act as a metastasis-promoting 
gene in various cancers including osteosarcoma, and could be an ideal prognostic biomarker 
for predicting osteosarcoma metastasis. The fact that the trend toward reduced overall 
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survival in the MTDH-high cohort did not reach statistical significance probably reflects the 
small sample size (n=71 total).  The analysis should be repeated with a larger number of 
clinical samples when they become available for osteosarcoma.  
MTDH promotes osteosarcoma metastasis by modulating cell motility and invasiveness 
The biological process of invading and filtrating into the surrounding ECM and the 
basement membrane is the first step of cancer metastasis. Therefore, the metastatic potential 
of a tumor cell is usually dependent on its motility and invasive ability. Previous studies in 
glioma and head and neck squamous cell carcinoma have demonstrated that MTDH promotes 
proteolytic digestion of the connections between tumor cells and ECM through activation of 
the MMPs including MMP1, MMP2 and MMP9  (70, 71, 84). Our data are consistent with 
recent findings in other tumor models showing that MTDH promotes metastatic 
dissemination of tumor cells through modulating cell migration and invasion.  
Both in vitro and in vivo studies clearly demonstrated that blocking MTDH is an 
effective way to inhibit the metastatic process, at least in these osteosarcoma models. 
Silencing endogenous MTDH by shRNA abrogated in vitro migration and invasion of human 
osteosarcoma cells without severely affecting their proliferation and clonogenic ability 
(Figure 17-20). In vivo experiments performed in an osteosarcoma mouse model of 
spontaneous pulmonary metastasis demonstrated that constitutive knockdown of MTDH 
delayed primary tumor growth and inhibited pulmonary metastasis (Figure 24-26). In 
addition, we saw a remarkable increase in MTDH expression in metastatic lesions in the lung 
as compared to the primary tumors resected from the mouse tibia (Figure 28), which is 
similar to what has been observed in clinical osteosarcoma samples (Figure 8). Overall our 
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data indicated a key role of MTDH in inducing the invasive properties in osteosarcoma cells. 
These findings have important clinical implications because MTDH, as a pivotal metastasis-
associated gene overexpressed in osteosarcoma, could be an ideal molecular target for 
preventing and treating metastatic disease. 
Functional significance of the cell surface localization of MTDH 
Regarding the mechanism by which MTDH mediates metastasis, Brown and Ruoslahti 
had proposed that cell-surface MTDH contains an extracellular lung-homing domain which 
mediates pulmonary metastasis by binding to an unknown ligand specifically expressed on 
lung endothelial cells (63). This report was the first to indicate the importance and potential 
functions of MTDH expressed on the surface of tumor cells. By using flow cytometry with 
an antibody reactive to amino acid residues 315-461 on the C-terminal segment of MTDH, 
we confirmed that MTDH localizes to the cell surface and has type II membrane topology in 
osteosarcoma (Figure 14 and 15). Our data demonstrated that osteosarcoma cells displayed 
abundant level of MTDH on cell surface as compared to the control osteoblasts (Figure 14).  
It is known that cell-surface proteins are often involved in mediating interactions 
between cells and its microenvironments. The cell-surface localization of MTDH in 
osteosarcoma provided revealing clues about its function and narrowed down the list of 
potential proteins that it may interact with. Through a series of in vitro functional studies, we 
have demonstrated that the cell surface distribution of MTDH is critical for its metastasis-
promoting function in osteosarcoma. Steric interference of the biological functions of the cell 
surface MTDH with antibodies targeting the extracellular C-terminal segment could 
efficiently inhibit cell migration, invasion, and adhesion to the ECM. Altogether, our 
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preliminary data in osteosarcoma cell models indicated that the invasion-promoting functions 
of surface-bound MTDH are independent of endothelial cell binding, which is inconsistent 
with the model proposed in Brown and Ruoslahti’s paper that MTDH contains an 
extracellular lung-homing domain.  
MTDH functions as a cell surface receptor for Laminin 
The processes of invasion and metastasis involve a complex cascade of events. One 
important property of metastatic tumor cells is the ability to attach to and migrate through 
basement membranes which comprise barriers against invading cells. Tremendous effort has 
been made in the past to define the role of proteases in degrading tumor matrix and 
surrounding tissue planes, but the mechanisms underlying tumor cell recognition, attachment 
to, and manipulation of these non-cellular stromal components remain incompletely 
characterized.  
Through a set of cell adhesion assays using osteosarcoma cells transduced with 
MTDH-specific shRNA or scrambled control sequence, we found that inhibition of 
endogenous MTDH resulted in significantly decreased adhesion to marigel and Laminin in 
vitro, while cell attachment to Fibronectin and Collagen IV was not affected (Figure 29). 
Similar effects were observed when we blocked the surface-bound MTDH with the anti-
MTDH antibodies (Figure 30). Considering the fact that matrigel is a gelatinous mixture of 
ECM proteins that resembles the complex extracellular microenvironment, MTDH may serve 
as an important mediator of cell-ECM interactions. The impaired cell adhesion to Laminin 
observed when MTDH was inhibited further suggested that Laminin could be the 
extracellular binding partner of MTDH. This hypothesis was validated by the bi-directional 
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co-immunoprecipitation performed with anti-MTDH and anti-Laminin antibodies, which 
demonstrated that MTDH and Laminin exist in the same protein complex when tumor cells 
interact with ECM (Figure 31 and 32). Our current study provides the first evidence that 
MTDH is a key regulator of cell-matrix adhesion in osteosarcoma, through which cell 
motility and invasiveness could be directly affected. Moreover, we have identified MTDH as 
a novel cell-surface interacting partner for extracellular Laminins. It will be of future interest 
to determine the region of MTDH that mediates binding with Laminin, which will enable 
better characterization of this interaction. 
Laminins, a family of secreted glycoproteins, are major components of extracellular 
matrix and basement membranes (100). They are composed of three different subunits, the α-
chain, β-chain, and γ-chain arranged in a cruciform shape (101). Laminins could form 
independent protein networks through connections with other ECM proteins such as 
Collagen IV, Enactin, Fibronectin, and Perlecan (102). They could also interact with cells 
through binding with the cell surface proteins including integrin receptors and various 
glycoproteins (102).  Through these interactions, Laminins have diverse biological functions 
including promoting cell adhesion and migration, initiating cell signaling pathways, and 
mediating cell differentiation and polarity (103). The significance of Laminin in tumor 
metastasis is well characterized (104). There is further evidence in osteosarcoma supporting a 
positive relationship between cell invasiveness and its ability to attach to Laminin (105, 106). 
By discovering the new connection between MTDH and extracellular Laminin in 
osteosarcoma, we improve our understanding of the mechanisms by which MTDH promotes 
metastasis. More importantly, these findings will establish a new paradigm for the function 
of MTDH in mediating tumor cell invasiveness. It is known that cancer cells need to invade 
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through basement membranes multiple times during their metastatic spread: starting with 
initial escape from the primary tumor, followed by intravasation and extravasation at 
secondary sites (107). For osteosarcoma, like many solid tumors, the spreading process also 
involves invasion into adjacent soft tissues and muscles. By incorporating this information 
into our present findings, here we propose a new model for the function of MTDH in 
metastasis (Figure 34).  
 
 
 
 
Figure 34. Schematic model of MTDH function.  In the upper left panel, a mass of tumor 
cells (blue) is seen extending via mass migration through extracellular matrix proteins and 
stromal elements toward a nearby blood vessel.  Laminin, normally present predominantly in 
the basement membrane, is depicted just outside endothelial cells.  MTDH mediates 
attachment to the basement membrane and orients the migration of cells toward the vessel.  
In the lower left panel, tumor cells have breached the endovascular space and access the 
bloodstream. On the right, the upper panel depicts lungs with metastatic tumors, and the 
lower panel depicts how MTDH-Laminin interactions might help mediate exit from the 
endovascular space once the pulmonary endothelial lining is disrupted. 
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Figure 34 
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Future Directions 
Mechanistic Studies 
Since we have identified the connection between MTDH and Laminin when tumor 
cells interact with the extracellular microenvironments, alternative strategies for blocking the 
interactions between MTDH and Laminin may provide additional approaches for preventing 
metastatic progression in addition to targeting MTDH itself.  Further mechanistic studies to 
define the protein domain structures, interactions and functions of MTDH are warranted. Our 
next step will be to determine if this interaction is governed by a direct physical association 
or mediated by another protein located on the cell surface or inside the ECM. To address this 
question, fluorescence resonance energy transfer (FRET) microscopy or bimolecular 
fluorescence complementation (BiFC) could be employed to display whether a close physical 
association between MTDH and Laminin exists in osteosarcoma.  
Future experiments will include mapping the specific protein domain on MTDH that is 
responsible for binding with extracellular Laminins through a series of protein truncation and 
site mutagenesis approaches. We are currently collaborating with the Center for 
Biomolecular Structure and Function of MD Anderson Cancer Center to develop purified 
protein fragments of MTDH. We propose to test each of these protein fragments for their 
ability to block the binding of osteosarcoma cells to Laminin. We will then use smaller 
fragments of the portion that blocks the binding to map out the region on MTDH that 
mediates the binding of the whole molecule to Laminin. These results will provide grounds 
for the development of therapeutic strategies that interferes with the interaction between 
MTDH and ECM. In the meantime, we plan to perform a yeast two-hybrid screening with 
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full-length MTDH cDNA and cDNA library from human osteosarcoma cell to identify 
potential intracellular MTDH-interacting proteins. 
We recognize that the interaction between MTDH and Laminin might be mediated by 
other cell-surface proteins or ECM constituents. Previous studies have shown that integrins, a 
family of integral membrane glycoproteins that mediate cell-cell and cell-ECM interactions, 
are the most common receptors for Laminins in various cell systems (108). The α, β, and γ-
chains of Laminin have all been shown to possess integrin-binding sites (108). Clustering of 
integrins on cell surface has been shown to promote adhesion, migration, invasion, and 
survival of tumor cells both in vitro and in vivo in a variety of human cancers (109-111). 
Knowing the essential function of integrins in tumor malignancy and their close association 
with Laminins, we want to investigate whether integrins are involved in the interaction 
between MTDH and Laminin. Since the expression pattern of integrins in osteosarcoma 
remains unclear, we will determine the expression level of various integrins in osteosarcoma 
cells by q-PCR and western blot, followed by co-immunoprecipitation experiments to study 
the association among MTDH, Laminins, and integrins. 
Translational Implications 
Our results collectively suggest that overexpression of cell-surface protein MTDH 
promotes metastasis in osteosarcoma. The therapeutic potential of manipulating MTDH is 
highlighted by the fact that the overall expression of this protein is dramatically upregulated, 
not only in osteosarcoma as shown here, but also in many other solid tumors (60, 63, 65, 70-
77).  More importantly, by identifying its cell surface localization we have provided 
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promising evidence that this protein will be easily accessible to therapeutic agents, which 
strongly supports the development of targeted therapies against MTDH.  
During the past 25 years, the therapeutic antibody technologies have undergone 
considerable development (112). Chimeric, humanized, and completely human monoclonal 
antibodies are gradually becoming important treatment options for cancer patients (113).  
These monoclonal antibody products, either in unconjugated forms or linked to cytotoxic 
molecules such as conventional chemotherapeutic agents, prodrug-converting enzymes, 
radioisotopes, and natural toxins, could recognize cell surface antigens that are specifically 
expressed on cancer cells and facilitate localized delivery and release of the toxic agents to 
the tumor sites (114-116). With the aid from the activated host immune system, therapeutic 
antibodies are able to induce a series of cytotoxic events such as cell cycle arrest and 
apoptosis to achieve clinical responses (115). Due to the high specificity and efficacy of 
antibody-based therapeutics, six types of these drugs have been approved by the FDA for the 
treatment of cancer (112). Knowing that MTDH is localized to the cell membrane as a type II 
transmembrane protein in osteosarcoma, its extracellular C-terminal segment which contains 
510 amino acid residues could be an ideal target for antibody-based immunotherapy. We 
expect the development of humanized monoclonal anti-MTDH antibody to improve the 
current therapeutic regimens for osteosarcoma patients and extend their survival. 
Another approach to target MTDH in clinic is to develop chimeric antigen receptor 
(CAR)-based therapies. This novel type of immunotherapy which incorporates the exquisite 
specificity of monoclonal antibodies with the long-term persistence of cytotoxic T cells has 
shown clinically-significant anti-tumor activities in a number of adult and pediatric 
malignancies (117, 118). In addition, current clinical trials in adults and pediatric patients 
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have demonstrated that the CAR therapy has high specificity and limited off-tumor toxicity 
for both short-term and long-term treatments (119-121). Since the efficacy of CAR therapy 
depends on the affinity of T cells to tumor cell-surface antigens, an ideal targeted protein 
should have abundant expression on the surface of tumor cells while having limited 
expression on normal tissue. Considering the discrete overexpression of MTDH in numerous 
cancer types, potential MTDH-targeted CAR therapy will have a wide range of applications 
in treating solid tumors in which effective control of metastasis is pivotal in improving 
clinical outcomes.  
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